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ABSTRACT

CYNTHIA DENISE BRADSHAW.

Roles of Phospholipase D and

Sphingomyelinase in T-Cell Signaling.

(Under the direction of

KATHRYN E. MEIER, Ph.D).

The overall goal of this study was to investigate the roles of
PLD and neutral SMase in signal transduction in T-Iymphocytes.
particular,

the

abilities of phospholipid

mitogen-activated

protein

kinases

metabolites to

were

explored.

The

In

regulate
tumor-

promoting PKC activator, phorbol 12-myristate 13-acetate (PMA),
and

an

antileukemic

drug,

1-8-D

arabinofuranosylcytosine

hydrochloride (Ara-C), were used as model phospholipase activators.
The effects of phorbol ester and Ara-C on PLD and SMase
activities were examined in EL4, a murine thymoma cell line, and
Jurkat, a human leukemia cell line.

PLD activity was measured in

intact cells using a metabolic labelling assay.
activities

were

measured

In

membrane

PLD and SMase
extracts

utilizing

fluorescent phosphatidylcholine (PLD) and sphingomyelin (SMase) as

x

substrates, respectively.

Rapid activation of PLD by PMA was

detected in Jurkat cells, but not in EL4 cells. Jurkat, but not EL4
cells, express a 120-kDa protein recognized by an anti-PLD antibody.
Ara-C activated neutral SMase within 10 minutes in both Jurkat and
EL4.

PMA did not activate SMase and Ara-C did not activate PLD.
The

relationships between activation of PLD,

members of the

SMase and

mitogen-activated protein kinase family,

(extracellular-regulated

kinases)

and

JNKs

(c-jun

ERKs

N-terminal

kinases), were examined using in vitro phosphorylation assays.

PMA

induced activation of ERKs in both Jurkat and EL4 cells, while Ara-C
or ceramides had no effect.

Incubation of EL4 cells with bacterial

PLD increased phosphatidic acid levels, but did not activate ERKs.
JNK activity was detected within 10 minutes after co-stimulation
with PMA and ionomycin in both EL4 and Jurkat cells.

Ara-C

activated JNKs in these cells only after prolonged incubation (90120 minutes). These results suggest that activation of PLD is
neither necessary nor sufficient for activation of ERKs or JNKs.

The

delayed effects of Ara-C on JNK activity may be mediated through
secondary response pathways.
The mechanism by which PMA activates PLD was examined In

XI

Jurkat cells and in a prostate cancer cell line.
obtained

for

PLD

protein kinase Ca.

translocation,

No evidence was

phosphorylation,

or binding

to

These results are consistent with observations

that PLD can be activated by protein-protein and/or protein-lipid
interactions.
The data obtained in these studies indicate that PLD and
neutral SMase are activated via distinct pathways in T-Iymphocyte
cell lines.

While their reaction products do not directly regulate

mitogen-activated

protein

kinases,

the

activation

of

these

phospholipases by mitogenic and cytotoxic stimuli suggest that
further understanding of the regulation of PLD and SMase and their
roles in signal transduction may present future avenues for the
improved therapy of T-Iymphocyte pathologies.
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CHAPTER 1

General

I ntrod ucti on

1.1

Phospholipases and Lipid Mediators in Signal
Transduction
Lipid mediators play crucial roles in signal transduction. These

molecules are considered important in cell proliferation, and in
processes involving cell-cell communication including host defense
and inflammation (Serhan et al., 1996).
phospholipases

within

individual

cell

types,

during

these

mediated

by

extracellular

signals

processes,

the initiating step in the biosynthesis of several

IS

generated

The activation of specific

multicellular

structurally diverse lipid mediators (Billah et al., 1990; Serhan e t
al., 1996). Phospholipases involved include phospholipase A2 (PLA2),
phospholipase C (PLC), phospholipase D (PLD), and sphingomyelinase
(SMase), each of which is pivotal in the biosynthesis of lipid
mediators (Billah et al., 1990; Serhan et al., 1996).

Activation of

these enzymes is accomplished by a wide range of agonists.

The

lipid mediators produced include free fatty acids, Iysophospholipids,
platelet activating factor (PAF), diglyceride (DAG), phosphatidic
acid, ceramide, and oxygenated fatty acid metabolites (Serhan et al.,
1996).

These

metabolites have been

implicated as essential

mediators in a variety of tissue and" cell functions.

2

Each major

group

of

phospholipase

(Figure

1-1)

contains

members that carry out similar reactions,
regulated

multiple

family

but are differentially

and can act on different substrates.

This diversity

provides alternative pathways for the highly controlled process of
phospholipid degradation and metabolism (Serhan et al., 1996).
PLA2 hydrolyzes several types of phospholipids to liberate free
fatty acids and Iysophospholipids, which may either exert direct
effects or serve as substrates for the generation of other lipid
messengers such as eicosanoids, lysophosphatidic acid, or plateletactivating factor (Balsinde et al., 1996).

Of particular interest is

the release of free arachidonic acid (AA), which serves as the
presursor for numerous bioactive eicosanoid products (Serhan et al.,
1996).

Mammmalian cells have been shown to contain multiple

structurally-diverse
different cellular

PLA2 enzymes (Dennis, 1994)..

At least three

PLA2S have been shown to play a role in the

mobilization of AA from phospholipids.

These include cytosolic

group IV PLA2S (Lin et al. , 1993; Kramer et al., 1993; Qiu et al.,
1993), the secretory group II PLA2S (Murakami et aI., 1993; Barbour

et al.,

1993;

Pfeilschifter,

1993),

and

a

cytosolic

calcium-

independent PLA2 (Lehman et al. , 1993; Ramanadham et al., 1993),

3

Eicosanoids

PC, etc

Receptor

t

- -__
...~Arachidonic acid +

PLA 2 LySo-PhOSPhOIiPld,,---.....PAF
PMA

PC - - - - -...~ PtdOH
... LPA
PLD
PI
.. DAG - - - -...~PKC
PI-PLC
+

T.

Cytokines
Ara-C -=::t=::t=--.

IP3

SM SMase ~

Membrane

PMA

... Ca++

Ceramjde

~

"
Kmases

0KC
,-,

phosphatases

FIGURE 1-1.
Overview of Lipid Mediator Function.
Each phospholipase is thought to be independently activated to
generate specific lipid-derived second messengers.
The relative
abundance of each pathway's enzymes and precursors are cellspecific. Modified from: Serhan, C.N. Haeggstrom, J.Z., and Leslie,
C.C. FASEB J. 10; 1147-1158, 1996.
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Cytosolic calcium-dependent PLA2 is a substrate for protein kinase
C (PKC), cyclic-AMP-dependent kinase, and ERK mitogen-activated
protein kinase (MAPK) in vitro

(Wijkander and Sundler, 1992; Lin et

a/., 1993; Nemenoff et a/., 1993; de Carvalho et a/., 1996).

It is

activated when phosphorylated by ERKs (Sa et a/., 1995; Clark et aI.,
1995).

Potential regulatory mechanisms for other forms of PLA2

have not been clearly defined.
PI-specific PLC hydrolyzes inositol phospholipids to generate
two second messengers,

inositol 1,4,5-triphosphate (IP3) and 1,2-

diacylglycerol (DAG) (Exton, 1994).

IP3 interacts with a receptor on

the endoplasmic reticulum to

release calcium from

stores (Bornfeldt et a/., 1995).

DAG is responsible for activating a

large

family

of

PKC

Isoenzymes

that

phosphorylation (Nishizuka, 1992; Bruch, 1996).

intracellular

catalyze

protein

Multiple isoforms

of PLC have been identified in a variety of mammalian tissues. The
different

isoenzymes

tyrosine kinases,

are

differentially

regulated

by

receptor-

non-receptor tyrosine kinases, G-proteins, and

calcium (Cockcroft et a/., 1992; Sternweis and Smroka, 1992).
Phospholipase D (PLD) and sphingomyelinase (SMase), the
topics of this thesis project, will be discussed in detail below.

5

1-2.

Protein Kinase C

Protein kinase C (PKC) consists of a family of related isoforms
of

serine/threonine-specifi.c

phospholipid-dependent

(Nishizuka, 1992; Blum et a/., 1994).
cellular

signaling.

kinases

PKCs are central elements in

Agonist-induced

membrane

phospholipid

degradation is required for PKC activation (Blum et a/., 1994).
step

allows

information

from

extracellular

long

term

differentiation

cellular
(Blum

to

be

Activation of PKCs are essential

transmitted across the membrane.
for

signals

This

responses

et al., 1994).

such

as

proliferation

and

Since PKCs play regulatory

functions in signal transduction (Nishizuka, 1986; Brook et a/., 1991;
Iwashita and Kobayashi, 1992), gene expression (Bernstein et al.,
1991;

Trejo

differentiation

and

Brown,

(Felipo

1991),

and

cell

proliferation

et a/., 1990; Minana et al., 1991),

and
these

enzymes are considered important in tumorigenesis and are a
potential target of new cancer therapies (Blum et a/., 1994).
PKCs exist as a family of 11
structures,

but

differ

developmental expression,
1995).

with
and

isoforms that have related

respect. to

tissue

specificity,

subcellular distribution

(Newton,

The isoenzymes have been grouped into three functional

6

classes based on their biochemical and structural properties and
cofactor regulation (Newton, 1995; Nishizuka, 1995).

The best-

described and first-discovered isoforms are the conventional PKCs
(cPKCs),
1995).

(I,

BI, BII, and 'Y (Liscovitch and Cantley, 1994; Newton,

cPKCs require either phospholipids, calcium, and DAG (or

tumor-promoting

phorbol

esters)

Cantley, 1994; Newton, 1995).

for

activity

for activity.

and

The next well-characterized group is

the novel PKCs, which include of 0, c, 11 (L),
Cantley, 1994; Newton, 1995).

(Liscovitch

e,

and Jl (Liscovitch and

This group does not require calcium

The least understood izoenzymes are the atypical PKCs

(aPKCs) which consist of
Newton, 1995).

~

and A (I) (Liscovitch and Cantley, 1994;

This group is not regulated by DAGs or phorbol

esters (Liscovitch and Cantley, 1994; Newton, 1995).

Each class of

PKCs appears to play distinct roles in controlling major cellular
fu nctio n s.

1-3.

Phospholipase D
Phospholipase 0

(PLD), first described in carrot roots and

cabbage leaves by Hanahan and Chaikoff (Heller, 1978), catalyzes the
degradation of phosphatidylcholine to phosphatidic acid plus choline

7

in the presence of water.

All early studies concerning the PLD

reaction were performed in plants.

Subsequent studies have shown

that PLD is expressed in microorganisms, mammals and yeast.
Phosphatidylcholine-preferring PLD can be detected in homogenates
and membranes from various mammalian tissues including lung,
liver, adipose tissue, endothelium and spermatozoa, with lung and
brain being the richest sources (Heller, 1978; Bocckino et al., 1987;
Tettenborn and Mueller, 1988; Martin, 1988; Anthes et al., 1991;
Geny et al., 1993; Stuchfield and Cockcroft,. 1993).

In plants and

microorganisms, the enzyme is found to exist in both particulate and
soluble forms (Heller, 1978).

In mammalian cells, PLD activity is

found to be associated primarily with particulate fractions (Heller,
1978).

However, one group was able to detect PLD activity in the

cytosol of various bovine tissues including lung, brain, spleen, heart,
kidney, thymus, and liver as well as in rat lung (Wang et al., 1991).
The different forms of PLD catalyze the same general reaction
(Heller, 1978; Liscovitch, 1989):

Phosphatidyl-R' + R"-OH

..

Phosphatidyl-R" + R'-OH

8

When R"

H, PLD catalyzes a hydrolysis reaction to produce

=

phosphatidic acid.

When R"-OH is an alcohol, PLD catalyzes a

transphosphatidylation reaction to produce phosphatidylalcohol.
variety of alcohols can serve as substrates (Ella et a/., 1997).

A
PLD

is unique from other phospholipases with respect to its broad
substrate

specificity, as well as in its abil ity to catalyze the

"transphosphatidylation"

reaction

(Heller,

1978;

Kobayashi

and

Kanter, 1987). Both hydrolysis and transphosphatidylation occur via
a common phosphatidyl-PLD complex formed by the nucleophilic
attack by PLD at the phosphorus of the substrate (Heller, 1978;
Kobayashi and Kanter, 1987).
with

The alcohol binding site associated

the transphosphatidylation

reaction appears to

be

largely

conserved between plant, yeast, and mammalian PLDs (Morris et al.,
1996).

1-4.

Regulation of Phospholipase 0
The activation

ot PLD has been implicated as a crucial step in

a broad spectrum of physiological processes and diseases, including
metabolic

regulation,

oncogenesis,

neural

inflammation,
and

cardiac

9

secretion,

stimulation,

mitogenesis,
diabetes,

and

senescence (Exton, 1994).

Since PLD has been identified as a

potentially important component of these processes, its modes of
regulation are under intense investigation.
In many cell types, PLD is activated in response to a diverse
array of growth factors and mitogenic agonists (Morris et al., 1996).
PLD has been shown to be activated by the same agonists that
activate

phosphatidylinositol-

and

phosphatidylcholine-utilizing

PLCs (PIP2-PLC; PC-PLC) (Thompson, 1991).

Reports have suggested

that activation of PLD can occur through multiple mechanisms
involving PKC, calcium ions, tyrosine kinases and/or GTP-binding
proteins such as Ras (Cockcroft, 1992; Exton, 1994), ARFs (Brown,
1993; Massenburg et al., 1994; Cockcroft et al., 1994), Rho A and B,
Rae and Cdc42 (Bowman et al., 1993; Exton, 1994; Siddiqi et al.,
1995).
There appear to be multiple isoforms of PLD.

Studies in

numerous mammalian tissues and cell lines have identified PLD
activities that differ in their subcellular localization, pH optima,
dependence on divalent cations, and susceptibility to inhibition by
fatty acids (e.g. oleate) and detergents (Morris et al., 1996).

These

results suggest the existence of PLD isozymes that differ with
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respect to activation mechanism, substrate specificity, and coStudies in Leydig cells have

factor requirements (Exton, 1994).

shown that PLD activated by phorbol 12-myristate 13-acetate (PMA)
preferentially hydrolyzes ester-linked phosphatidylcholine, whereas
PLD activated by a G-protein-coupled receptor does not discriminate
between ether- and ester-linked phosphatidylcholine (Lauritzen and
Hansen, 1995).

In contrast, Huang ,and co-workers (1992) using

MOCK cells, showed that PMA-activated PLO selectively hydrolyzes
ether-linked phosphatidylcholine, while ARF- or ·Rho-regulated PLD
preferentially

hydrolyses

ester-linked

phosphatidylcholine.

Even

though most forms of PLO prefer phosphatidylcholine, it has been
shown

that

the

cytosolic

phosphatidylcholine,

but

form
also

of

PLD

not

only

hydrolyzes

phosphatidylethanolamine

phosphatidylinositol (Wang e tal., 1991).

and

Phosphatidylserine and

phosphatidylethanolamine are both utilized by a recently-described
yeast PLD that is calcium-dependent and does not perform a
phosphatidylation reaction (Mayr et al., 1996).
The involvement of PKC in the activation of PLD has been
demonstrated by several approaches..

Treatment of cells with

phorbol 12-myristate 13-acetate (PMA), an activator of PKCs, can
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activate PLD but not PLC.

More recently, a role for specific PKC

isozymes in the regulation of PLD was shown by studies in which
PKCa

or

- B were

overexpressed

(Ohguchi

et

at.,

1996).

Overexpression of PKCBI enhances PMA-induced PLD activity in rat
fibroblasts (Pai et al., 1991). Overexpression of PKCa in Swiss-3T3
fibroblasts
stimulated

(Eldar et at.,

1993)

elevates

basal

and

PLD activity in intact cells as well as In

agonistvitro.

In

membranes isolated from CCL39 fibroblasts (Conricode et al., 1994),
only PKCa and -8 are capable of activating PLD.

These results

suggest that activation of PLD may be selectively mediated by
particular PKC isoforms.
The exact mechanism by which PKC activates PLD is not fully
understood.

It is possible that PKC directly interacts with PLD in

membranes, or that PKC interacts with other membrane-associated
proteins that in turn activate PLD (Ohguchi et ai, 1996).

Conricode

an co-workers (1994) have shown that PMA activation of PLD
involves PKC but does not require ATP-dependent phosphorylation in
Chinese hamster lung fibroblasts.
workers

According to Singer and co-

(1996), PKC may regulate signaling events through direct

molecular interaction with downstream effectors as well as through
12

its

well-characterized

catalytic

modification

of

proteins

by

phosphorylation.
In cell-free preparations from several tissues, PLD activity is
enhanced by the addition of calcium.

Calcium is also required for

GTPyS-stimulated PLD activity in granulocyte homogenates (Anthes
et al.,

1991;

Xie

and

Dubyak,

1991)

and

for

ATP-induced

phosphocholine formation in hepatocyte membranes (Irving and
Exton,

1987).

hepatocyte

By contrast,

membranes,

in

several

homogenates

preparations,
from

including

endothelial

cells

(8occkino et al., 1987; Martin, 1988), spermatozoal extracts (Domino
et al., 1989), and some T-Iymphocytes, PLD activities do not require

calcium.

This suggests that calcium requirement for PLD may vary

among cell types, that some forms of PLD may require calcium,
and/or that calcium may be indirectly effecting PLD through some
unknown mechanism.

Mayr and co-workers (1996) have identified a

strictly calcium-dependent PLD in Saccharomyces cerevisiae.

This

60kDa

and

PLD

preferentially

phosphatidylethanolamine.

hydrolyzes

phosphatidylserine

Unlike previously-characterized plant,

yeast, and mammalian PLDs, this calcium-dependent PLD is not
affected by P1P2 and does not catalyze a transphosphatidylation
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reaction in the presence of alcohol (Mayr et a/., 1996).

It appears

that this calcium-dependent PLD is a member of a novel family of
PLDs.

Since mammalian PLDs are usually assayed through use of the

transphosphatidylation

reaction,

it is

not yet clear whether a

similar calcium-dependent enzyme is expressed in mammalian cells.
A strong correlation between tyrosine phosphorylation and PLD
activation was established in studies performed by Bourgoin and
Grinstein (1992), in which treatment of permeabilized HL-60 cells
with vanadyl hydroperoxide induced the accumulation of tyrosinephosphorylated proteins along with an increase in PLD activation.
Uings and co-workers (1992) showed that three tyrosine kinase
inhibitors blocked the activation of PLD induced by several agonists
in

neutrophils,

whereas

pervanadate

phosphorylation and PLD activity.

increased

tyrosine

These results suggest that PLD

can be activated by an increase in tyrosine phosphorylation, thereby
providing a role for tyrosine kinases in the regulation of PLD.
Monomeric G proteins have been implicated as regulators of
PLD in many mammalian cell types.

Studies by Carnero and co-

workers (1994) have shown that, in NIH3T3 fibroblasts, mitogenic
stimulation induced by Ras oncogenes is functionally linked to
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activation of PC-PLD.

Several other groups have identified ARF

proteins as effective activators of PLD in HL-60 cells (Brown et al.,
1993; Cockcroft et al., 1994b). ARF is a 21 kOa guanine nucleotidebinding protein that is responsible for enhancing the cholera toxin
catalyzed

ADP-ribosylation of the Gsa

subunit that stimulates

adenylate cyclase (Ding et aI, 1996). ARF has also been identified as
an essential component of pathways for protein trafficking in cells.
The small GTP-binding proteins of the Rho family, Rho A and B Rae, and Cdc42 , are implicated in signal transduction pathways
t

that regulate both the actin cytoskeleton and mitogen-activated
protein kinase (MAPK) cascade.

The involvement of these proteins in

the activation of PLD was demonstrated by Exton and colleagues,
who showed that treatment of plasma membranes from rat liver
with Rho-GOt reduced guanine nucleotide-stimulated PLD activity
(Siddiqui et al., 1995).

This activity could however be restored with

the addition of purified RhoA protein.

Subsequent studies revealed

that a partially purified PLD preparation from porcine brain, as well
as PLD activities in cytosol and membranes of HL-60 cells, could be
activated by ARFs and by Rho A and
1996).

~B,

Rae and Cdc42 (Morris et al.,

Rho A has been shown to act synergistically with PKC to
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stimulate activation of membrane-associated PLD activty in HL-60
cells (Ohguchi et al., 1995; Ohguchi et al., 1996). Rho A and ARF can
also exert a synergistic effect on PLD activation in several cell
types, including HL-60 cells (Siddiqui et al., 1995; Morris et al.,
1996).

Rho-specific GDP dissociation

inhibitor can

suppress

synergistic PLD activation by GTPys and protein kinase C in HL-60
membranes (Malcolm et al., 1994).

These synergisms suggest that

Rho A may be cooperatively regulating ARF- and protein kinase Cinduced PLD activity in HL-60' cells (Siddiqui et al. , 1995). Rac1 has
been shown to play a major role in the activation of PLD by
epidermal growth factor in Rat1

fibroblasts (Hess et al., 1997).

Additional studies have shown that ARF- and Rho-responsive PLD
activities

are

specifically

4,5-bisphosphate is

stimulated

included

in

when

phosphatidylinositol

the

substrate-containing

phospholipid vesicles (Morris et al. , 1996).

These results further

suggest a role for this phospholipid as a cofactor or mediator of PLD
activation.
PLD can be negatively regulated by cellular cytosolic factors.
According to Lukowski and co-workers (1996), a major increase in
the total

PLD activity was observed during an initial step of
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purification of cytosolic PLD activators, suggesting the removal of
an inhibitor.

This group was later able to show that fodrin, a high

molecular mass, cytoskeletal protein, was responsible for inhibiting
PLD activity.

A specific protein from bovine brain cytosol has been

identified that potently inhibits PIP2-dependent PLD activity (Kim et

al.,

1996).

This

30-kDa

inhibitor

specifically

regulates

PLD

activity, but does not bind substrate vesicles containing PIP2.

In

addition, the suppression of PLD activity by the inhibitory protein
can be reversed by the addition of ARF.
further

evidence

for

the

involvement

negatively regulating PLD activity.

These results provide
of

cytosolic

factors

in

The role of such factors In

regulating PLD activity in intact cells is not clear.

PLD activity can

also be negatively regulated in intact cells via the heterotrimeric Gprotein, Gi (Ella et al., 1997).
Despite the wealth of information concerning the biochemical
properties of PLO, relatively little is known about its structural and
molecular properties.

An attempt to answer these issues led to ,the

identification and characterization of a PC-specific PLD activity In
plants (Wang et al., 1994).
identification

of

the

gene

The cloning of this gene assisted in
encoding
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a

phosphatidylcholine-

hydrolyzing PLD1 in the yeast, Saccharomyces cerevesiae (Ella et al.,
1996).

This gene is localized to the site of the SP014 sporulation

mutation

(Waksman

et al. ,

1996),

and

encodes

transphosphatidylating catalytic activity (Ella
al., 1996).

et

a

PLD

with

al., 1995; Ella

et

Additional studies, using yeast PLD1 as a tool, led to the

cloning and characterization of human PLD1 (Hammond et al., 1995).
hPLD1

is

membrane-associated

and

IS

activated

by

phosphatidylinositol 4,5-bisphosphate and by ARF (Hammond et al.,
1995).

A splice variant of this gene was recently characterized

(Hammond ef al. , 1997).

The characterization of each of the PLDs

encoded by each of these genes will be essential for revealing
structural features of PLDs and their mechanisms of regulation.

1-5.

Mechanism

of Action of Phosphatidic Acid

Phosphatidic acid (PA), product of the reaction catalyzed by
PLD, may act as an intracellular second messenger in PLD-mediated
signaling processes.

The role of PA has been difficult to establish

because this substrate is taken up poorly by cells, and can be
metabolized on the outer surface of the cell.
mitogenic for some mammalian cell types.

18

Nonetheless, PA is
In epithelial cells, PA

has been shown to increase release of calcium from intracellular
stores and to stimulate synthesis of DNA (Moolenaar et aI., 1986). In
3T3 fibroblasts, PA is highly mitogenic.

This effect can. be seen

following down-regulation of PKC, but is blocked by antibodies to
ras proteins {Yu et al., 1988}.

Additional studies in 8alb/c 3T3

celis, using monoclonal antibodies to PA to quantify levels of PA,
have

also

suggested

that

PA

accumulation

mitogenesis (Fukami and Takenawa, 1992).

is

important

in

All of these studies are

complicated by potential metabolism of PA to active metabolites
such as LPA.
The molecular targets of PA remain poorly defined.
stimulate

protein

phosphorylation

when

(80cckino et al., 1991; Meier, 1992).

added

to

cell

PA can
extracts

In human platelets, a PA-

activated protein kinase has been characterized (Khan et al., 1 994).
PA has been shown to inhibit the GAP-mediated stimulation of the

GTPase activity of Ras in vitro, as well as to stimulate activation of
ARF-GAP proteins (Tsai et al., 1989).

PA has also been shown to

activate Ras-related p21 Rae-GAP activity (Ahmed et al., 1993). PA
can bind to Raf-1 and enhance its activity (Ghosh et aI.., 1 996) .
However, it has been difficult to address the significance of these
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effects in intact cells.
Lysophosphatidic acid (LPA), a product of PA metabolism and a
contaminant of PA preparations, can act as an extracellular signal.
LPA has been shown to be mitogenic in some cells (Moolenaar et a/.,
1986), and to activate PLD (Van der Bend et a/., 1992).

There is

increasing evidence that many cells possess a surface receptor for
LPA (Thomson et a/., 1994).

The function of this receptor is often

blocked by pertussis toxin, an inhibitor of Gj-mediated
(Nagami et a/., 1995).

signalling

Thus, many of the actions of LPA, such as PI

hydrolysis, calcium elevation, AA release, inhibition of adenylate
cyclase, chemoattraction, and PLD activation, can be attributed to
receptor-activated G-protein-mediated mechanisms.

LPA can also

induce activation of ERK mitogen-activated protein kinases via Ras
and Raf (Howe and Marshall, 1993; Hordijk et a/., 1994).

This action

can be mediated by activation of c-Src (Luttrell et al., 1996).

LPA is

a strong activator of Rho-dependent signal transduction pathways
(Ahmed et al., 1993).

While LPA can be released by platelets (Ohata

et a/., 1996) and is a major growth factor in serum (Krebs et a/.,

1993), its potential roles as an autocrine or paracrine mediator have
not been adequately explored.
20

1-6.

Roles

of Sphingolipids

in

Signal

Transduction

Based on the examples for glycerol-phospholipids, the roles of
sphingolipids

In

signal

transduction

have

been

examined.

Sphingolipids are complex lipids that serve a structural role in
membranes.

Sphingolipids consist of a long chain amino dialcohol

base (sphingoid), an amide-linked fatty acyl group, and a polar or
glycosidic head group (Hannun and Bell, 1993).

The simplest

sphingolipid, ceramide, serves as a precursor for more complex
sphingolipids (Hannun and Bell, 1993).

These include sphingomyelin,

a major constituent of most membranes in eukaryotic cells, as well
as neutral glycolipids and more complex acidic glycosphingolipids
(Hannun and Bell, 1993).
Sphingolipids have roles in the response to cell contact, as
receptor components, as anchors for proteins, and as markers of
tumor progression and cell differentiation (Hannun and 8ell, 1993).
Sphingolipids also play a significant role in the regulation of cell
viability (Hannun, 1996).
mammalian

cells,

sphingolipid

biosynthesis

abolition

In both Saccharomyces cerevisiae and

mutations

in

the

first

(serine-palmitoyl

of sphingolipid formation
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enzyme

in

transferase)

de novo
result

In

and loss of viability that is

reconstituted by replacement with sphingolipids (Hannun, 1996).
A potential
became

evident

role

for sphingolipids as signaling

with

the

demonstration

that

molecules

sphingosine,

an

endogenous sphingolipid metabolite, reversibly inhibits PKC (Hannun
et al., 1986).

This observation prompted further investigations that

led to the discovery of a sphingomyelin cycle of cell regulation and
the potential role of ceramide as a second messenger/intracellular
mediator (Hannun and Bell, 1989).

1-7.

Sphingomyelin

Cycle

The sphingomyelin cycle (Figure 1-2) was first characterized
by Okazaki and co-workers in human HL-60 leukemic cells (Okazaki
et al., 1989).

When these cultured cells were labeled with choline

and then stimulated with 1-a,25-dihydroxyvitamin
sphingomyelin

changed

substantially,

indicating

03, the levels of
hydrolysis

of

cellular sphingomyelin to generate choline phosphate and ceramide
(Okazaki et al.,

1989).

Other investigations were subsequently

performed to examine the components of the sphingomyelin cycle,
the

hormone-activated

enzymes

regulating

sphingomyelin

hydrolysis, the role of sphingomyelin hydrolysis and the generated
22

Sphingomyelin
PC: ceram ide choline
phosphotransferase

Choline-

Phosphate

Ceramide

Cellular

Responses

FIG URE 1-2.
The sphingomyelin cycle.
Sphingomyelin is cleaved by sphingomyelinase to yield
ceramide and choline phosphate. Sphingomyelin is regenerated from
ceramide via the transfer of choline phosphate from
phosphatidylcholine by action of phosphatidylcholine:ceramide
choline phosphotransferase. Adapted from: Saba J. D., Obeid, L.M., and
Hannun, Y.A. phUns. Trans. B. Soc. London B. BioI. Science. 351; 233240, 1996.
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products in biological responses, and the extracellular inducers of
/

\
sphingomyelin hydrolysis (Hannun and Bell, 1993).

Evidence obtained

thus far suggests that the sphingomyelin cycle is involved in the
regulation of cell growth, differentiation, programmed cell death,
and cell attachment (Hannun, 1994).
The major components of the sphingomyelin cycle

are: a}

sphingomyelin, the substrate; b} sphingomyelinase, the enzyme that
catalyzes the hydrolysis of sphingomyelin; c} ceramide and cholinephosphate, products resulting from the hydrolysis of sphingomyelin;
and d) the enzymatic pathway for the resynthesis of sphingomyelin
(Kolesnick and Golde, 1994) (Figure 1-2).

The enzymatic pathway

for the resynthesis of sphingomyelin from ceramide occurs via the
transfer of choline phosphate from phosphatidylcholine by action of
phosph atidyl cho line :ce ra m ide

ch 0 Ii ne

phosph otransfe rase.

Sphingomyelin is a naturally-occurring membrane lipid that is
preferentially localized in the outer leaflet of the" plasma membrane
of mammalian cells (Kolesnick, 1991).

Sphingomyelin is composed

of

backbone

a

long

sphingosine),

chain
a

fatty

sphingoid-base
acid,

and

(Kolesnick, 1991; Saklatvaia, 1995).
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a

(predominantly

phosphocholine

headgroup

Sphingomyelin is hydrolyzed

via a PLC-like reaction catalyzed by the enzyme sphingomyelinase
(SMase) (sphingomyelin phosphodiesterase) (Zhang and Kolesnick,
1995) into phosphocholine and ceramide.

The phosphocholine head

group is released into the extracellular environment while ceramide
is thought to diffuse within membranes, acting as an intracellular or
membrane-localized messenger (Testi, 1996).
Hydrolysis of sphingomyelin to ceramide has been described in
a variety of cell lines in response to various stimuli, including 1(l,25-dihydroxyvitamin

D3 (Okazaki et al., 1989; Okazaki et a I.,

1990), diacylglycerols (Testi, 1996), ionizing radiation (HaimovitzFriedman

et al.,

1994), progesterone (Strum et al., 1995), and

chemotherapeutic agents (Strum

et a/., 1994).

Accumulation of

ceramide derived from sphingomyelin hydrolysis can also result
from binding of ligands to cell-surface receptors, including tumor
necrosis factor receptor (Dressler et al., 1992; Yanaga and Watson,
1992; Dbaibo et al., 1993; Kim et al., 1994), interleukin-1J3 receptor
(Ballou

et a/., 1992; Mathias et al., 1993), nerve growth factor

receptor (Dobrowsky et al., 1994), FAS/APO-1 antigens (Cifone e t
al., 1993), and CD28 (Testi, 1996).

coupling

these

receptors to

The mechanisms responsible for

SMase
25

activation

have

not been

identified.

1-8.

Sphingomyelinases
Sphingomyelinases

intracellular
considered
Several

(SMases),

degradation
essential

forms

of

of

have

mammalian tissues and organs.
first two enzymes identified.
signal-specific

biological

are

sphingomyelin

components

SMase

which

of

the

been

to

responsible

for

ceramide,

are

sphingomyelin

identified

in

cycle.

variety

of

Acid and neutral SMases were the
They are suggested to participate in

processes

(Spence,

1994;

Chatterjee,

1994). The other forms of SMase include a cytosolic SMase (Okazaki
et al., 1994), a zinc-stimulated SMase (Spence et al., 1989; Schissel
et al., 1996), and an alkaline SMase (Duan et al., 1995; Nyberg et al.,

1996).
Acid SMase is a lysosomal hydrolyase that is ubiquitously
distributed in all tissues.

Acid SMase acts optimally at pH of, 4.5-

5.5 in vitro (Spence, 1994).

This enzyme does not require a cofactor

for maximal activity and

not affected by EDTA or Triton X-100

(Kolesnick et al., 1991).

IS

Acid SMase activity is, however, inhibited

by the thiol reagent dithiothreitol (OTT) and by some lipids and
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detergents, such as fatty acids, sphingosine, and sodium dodecyl
sulfate (SDS) (Maruyama and Arima, 1989).

Kronke and co-workers

(Wiegmann et al., 1992; Schutze et al., 1994) have suggested that
acid SMase may be activated by some agonists. In this case, acid
SMase

is activated by DAG generated by a ligand-responsive

phosphatitdylcholine-specific PLC (Wiegmann et al., 1992; Schutze

et al., 1994).

Mutation of acid SMase results in the two major

subtypes of human Neimann-Pick Disease
disorder

characterized

(Schuchman

et al., 1991).

by

(NPD), an

accumulation

of

inherited

sphingomyelin

Type A NPD is a rapidly progressing

neurodegenerative disorder (Schuchman et al., 1991). Type S NPD
causes

manifestations

limited

to the

reticuloendothelial

system

(Schuchman et al., 1991). Three human acid SMase cDNAs have been
isolated and sequenced from fibroblast, placental, testis, hepatoma,
and retinal cDNA libraries (Schuchman et al., 1991).

Transient

expression studies showed that type 1 transcript, the major species,
encodes

a catalytically active

enzyme.

Sphingolipid

activator

proteins (SAPs), or saposins, play a role in the hydrolysis of
sphingomyelin via acid SMase (Kolesnick, 1991).

Saposins (A, S, C,

and D), are a group of homologous glycoproteins derived from a
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single precursor,

prosaposin,

that enhance

lysosomal hydrolase

action (Kolesnick, 1991; Vaccaro et al., 1995).
proteins

was

requirements

originally

described

in vitro (Kolesnick, 1991).

as

The action of these

replacing

detergent

Saposins A, B, and D have

SMase-enhancing capabilities, while saposin C, also known as SAP-

2, enhances hydrolysis of sphingomyelin, glucosylceramide, and
galactosylceramide by

~-glucosylceramidase

(Qi et al., 1996).

Neutral SMase is a membrane-bound enzyme that is thought to
be co-localized with its substrate on the outer leaflet of the plasma
membrane (Ghosh and Chatterjee,1987; Chatterjee, 1993).

This

enzyme requires divalent cations such as magnesium for activity
(Ghosh and Chatterjee,1987; Kolesnick, 1991; Chatterjee,
Neutral SMase has an optimal pH of 7.0-7.5.

1993).

This enzyme can be

activated in response to a number of extracellular stress-related
stimuli.

High levels of activity can be detected in brain and neural

tissues (Chatterjee, 1993).
important

in

generating

functions

including

Neutral SMase is believed to be most
lipid

messengers

proliferation,

(Chatterjee, 1993; Hannun, 1994).

to

differentiation,

regulate
and

cellular

apoptosis

A neutral, Mg2+-dependent SMase

has also been identified in S. cerevisiae (Ella et al., 1997).
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Okazaki and co-workers (1994) described a cytosolic SMase
activated

In

HL-60

dihydrovitamin D3.

cells

upon

stimulation

with

1-c:x , 25-

This enzyme has optimal activity at neutral pH

and does not require magnesium for activity.
inhibited by copper, ferric iron, and zinc.

Cytosolic SMase is

Activity of this enzyme IS

modestly enhanced by phosphatidic acid, phosphatidylserine, or
phosphatidylinositol, but not by other major phospholipids (Okazaki
et al., 1994).

Cytosolic, magnesium-independent SMase is reportly

activated during cell differentiation (Okazaki et al., 1994).
Zinc-stimulated SMase, originally described by Spence and coworkers (1989), was detected in fetal bovine serum and, in lower
levels, in newborn human serum.

Recent studies, have shown that

zinc-SMase activity is secreted by human and murine macrophages,
human skin fibroblasts, microglial cells, and several other cells in
culture (Schissel et al., 1996).

Zinc-SMase arises from the acid

SMase gene independently of alternative splicing, suggesting a posttranslational modification (Schissel et al., 1996).

This enzyme has

optimal activity at a pH of 5.5 (Spence et al., 1989; Schissel et al.,
1996).

Zinc-stimulated SMase is inhibited by AMP and EDTA

(Schissel et al., 1996).

The biological function of zinc-stimulated
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SMase is unknown.

However, it is hypothesized that this enzyme

may play roles in physiological and pathophysiological processes
involving

extracellular sphingomyelin

hydrolysis

(Schissel

et al. ,

1996) .
Alkaline SMase is thought be a potential player in digestion of
dietary sphingomyelin and in gallbladder diseases (Duan et al., 1995;
Nyberg et al. , 1996).

Alkaline SMase has an optimal pH of 9.0 (Duan

et al. , 1995; Nyberg et al. , 1996). This enzyme is enriched in brushborder preparations of rat intestinal mucosa and is present in human
duodenal content and meconium (Duan et al., 1995).

It is also

present in both human hepatic bile and gallbladder bile (Nyberg

al., 1996).

et

The activity of alkaline SMase is dependent on bile salts,

but is not increased by Triton X-100.

Calcium or magnesium does

not change the activity of this enzyme in the presence of bile salts
(Nyberg et al., 1996).

1-9.

Ceramide:

An

Intracellular Second

Messenger

Ceramide is a central molecule In sphingolipid structure and
metabolism

(Hannun,

1994).

The

activation

of

cellular

sphingomyelinase generates ceramide along with phosphocholine.
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These products are then recycled back to sphingomyelin, defining the
sphingomyelin cycle (Hannun, 1994).
Biological studies utilizing ceramide analogs have indicated
that ceramide possesses biological activity and can directly affect
cell growth and differentiation (Obeid and Hannun, 1995).

Short-

chain C2-, C6- and C8-ceramides are widely used as cell-permeable
analogs to examine effects of ceramide on intact cells (Hannun,
1994). Their use was first demonstrated in HL-60 cells, in which
exposure to C2-ceramide resulted in a' dose-dependent inhibition of
cell

proliferation

that

was

accompanied

monocytic phenotype (Kim et al., 1991).
induced

transcriptional

down-regulation

by

induction

Futhermore,
of

the

of

the

~-ceramide

c-myc

proto-

oncogene by blockade of transcriptional elongation (Kim et al.,
1991).

These results suggest that ceramide-induced effects on cell

proliferation may involve control of c-myc mRNA levels (Kim et al.,
1991).

The effects of ceramide on cell differentiation have been

extended to a number of other cell systems, such as T9 glioma cells
and fibroblasts.

Ceramide is also thought to play a role in the

regulation of the transcription factor NFkB (Obaibo et al., 1993;
Hannun and Obeid, 1995).

Ceramide appears to activate NFkB poorly
31

/

when applied to intact cells, but effectively In permeabilized cells
(Dbaibo et al., 1993; Hannun and Obeid, 1995).

This raises the

possibly that ceramide may be necessary but not sufficient for
activation of NFkB (Obaibo et al., 1993; Hannun and Obeid, 1995).
Early investigations of the biological activity of ceramide
analogs were hindered by their potent cytotoxic effects.
cytotoxicity

was

stereoisomer-specific,

implying

that

The

ceramide-

induced cytotoxicity was likely to be the result of an interaction
between ceramide and a biological receptor, rather than the result
of a nonspecific detergent-like effect on membrane integrity (Saba
et al., 1996).

In addition, molecules closely related to ceramide,

such as dihydroceramide, lacked any significant cytotoxic activity
(Pushkareva et al., 1995).

This lead to the suggestion that ceramide

may be a mediator of apoptotic cell death.
Obeid and co-workers (1993) demonstrated the ability of C2ceramide to induce programmed cell death in U937 monoblastic
leukemic cells.

Ceramide potently induced internucleosomal DNA

fragmentation.

The effects were specific in that closely-related

analogs of ceramide, such as DAG and dihydroceramide, were
inactive (Jarvis et al., 1994).

Apoptosis can also be induced in other
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(
cell systems using Ca-ceramide (Jarvis et al., 1994).

As is the case

for other agonists that induce programmed cell death, the effects of
ceramide can be inhibited by the addition of zinc, suggesting the
involvement of calcium-dependent endonuclease (Pushkareva et al.,
1995).

Other studies have suggested that ceramide may also

participate in apoptosis induced by dexamethasome, crosslinking of
antibodies, FAS ligand, or serum withdrawal (Pushkareva et al.,
1995).

Obeid and co-workers (personal communication) have shown

that transfection of a bacterial neutral SMase results in apoptosis
of

mammalian

cells,

while

incubation

exogenous bacterial SMase does not.

of

the

cells

with

the

These results suggest that

despite the localization of sphingomyelin and/ or SMase to the outer
leaflet of the plasma membrane, ceramide must be generated within
cells to initiate apoptosis.
A role for ceramide In cell-cycle regulation has also been
proposed.

In MOL T-4 leukemic cells, it was shown that serum

withdrawal

resulted

(Jayadev et al., 1995).

in

significant

accumulation

of

ceramide

This was concurrent with the development of

cell-cycle arrest in GO/G1 and initiation of apoptosis (Jayadev
al., 1995).

et

When MOLT-4 cells were treated with Cs-ceramide, a
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specific arrest in the GO/G1 phase of the cell cycle was observed
that was both dose- and time-dependent (Pushkareva et al., 1995).
The retinoblastoma (Rb) gene product is centrally involved In
regulation

of the

progression,

mammalian

particularly

(Weinberg, 1991).

in

cell

cycle.

response

to

It inhibits cell-cycle
growth

suppressors

The effects of ceramide on Rb phosphorylation

were examined in MOLT-4 cells (Dbaibo

et al., 1995). The addition of

C s-ceramide, in concentrations similiar to those achieved during
serum

deprivation,

resulted

dephosphorylation of Rb.

in

a

tim-e-

and

dose-dependent

Subsequent studies performed in Rb-

deficient cells showed them to be resistent to ceramide-mediated

g r0 wt h i nh i bit ion.

Cell

lines that expressed

either the

tumor

antigen SV40 or adenovirus EIA were also unresponsive to the
growth-inhibitory effects of ceramide (Dbaibo et al., 1995).

These

results indicate that ceramide may participate In an Rb-dependent
pathway leading to cell cycle arrest (Pushkareva et al., 1995).
Ceramide levels were found to be significantly elevated In
senescent cells, which are unable to undergo DNA synthesis or
proliferative responses to serum stimulation (Venable et al., 1994).
A role for ceramide in inducing senescence was demonstrated by its
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ability to induce Rb dephosphorylation and cell cycle arrest in human
diploid fibroblasts.

Exogenously administered ceramide inhibited

DAG generation and PLD activation in WI-38 human fibroblasts, thus
mimicking the lack of PLD activation seen in senescent cells.
Ceramide is also suggested to interact with the components of
other signaling pathways.

It was shown that C2-ceramide markedly

enhanced the production of PGE2 in response to stimulation of human
dermal fibroblasts with IL-1 (Ballou et al., 1992).

Further studies

reported that ceramide treatment also induced the expression of
cyclooxygenase gene mRNA, and an increase in cyclooxygenase
protein levels (Ballou et al., 1992).

Cyclooxygenase is the rate-

limiting enzyme in the synthesis of PGE2 (Ballou et al., 1992).
Ceramide has also been implicated in the regulation of PLD
(Venable et a/., 1996).

In HL-60 cells, ceramide has been shown to

inhibit phorbol-ester-induced PLD activation.

Ceramide did not

interfere with translocation of protein kinase C to the membrane in
response to phorbol ester.

In a cell-free HL-60 system, ceramide

interfered with PKC-mediated activation of PLD.
Similiar to the effects observed in various mammalian cell
lines, it has been found that growth of Saccharomyces cerevisiae is
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markly inhibited by C2-ceramide (Fishbein et al., 1993).
is

dose-dependent,

stereospecific,

and

can

be

This effect
elicited

by

phytoceramide, the naturally-occuring yeast ceramide, but not by
dihydroceramide

et al., 1993).

(Fishbein

Sphingosine

and

phytosphingosine can also inhibit yeast growth (Ella et al., 1996).

A

ceramide-responsive phosphatase activity was identified in crude
extracts of Saccharomyces cervisiae (Fishbein et al., 1993).

While a

SMase with activity at acid and neutral pH has been identified in
yeast, it is not yet clear whether this enzyme hydrolyzes endogenous
yeast sphingolipids.
In summary, the available data indicate that ceramide serves
as a lipid mediator in mammalian cells.

However, the lack of

information

regulation

concerning

the

structure

and

of

neutral

SMase has impeded progress in this area.

1-10.

Molecular Targets of Ceramide

Action

Ceramide is postulated to serve as a second
molecule.
identified.

Several

potential

targets

for ceramide

messenger
have

been

To exert its biological effects, ceramide may transduce

intracellular signals by activating protein kinases (Mathias et aI.,
36

1991; Liu et al., 1994) or protein phosphatases (Drobrowsky and
Hannun,

1993).

Kolesnick and co-workers (Kolesnick and Golde,

1994) have described a ceramide-activated protein kinase (CAPK) in
A431 human epidermal carcinoma and HL-60 cells.

This enzyme

appears to phosporylate the epidermal growth factor receptor and is
activated by TNF-a and IL-1 (Kolesnick and Golde, 1994).
specificity

of

ceramide

activation

of

CAPK

nor

Neither the
its

role

in

intracellular signaling have been fully elucidated.
PKC-~

is also a postulated target for ceramide action.

isozyme of PKC is not activated by DAG or phorbol esters.

This

PKC-~

can

be activated by ceramide in vitro and has been shown to play a role
in ceramide- and TNF-a induced activation of the NFkB transcription
factor (Lozano et al., 1994).
Ceramide-activated protein phosphatase (CAPP)
target for ceramide action.

is another

This phosphatase belongs to the class

2A (PP2A) family of serine/threonine protein phosphatases (Hannun,
1994).

Studies using purified and reconstituted PP2A have shown

that ceramide activates only heterotrimeric PP2A, and that the
presence of the B-regulatory subunit of PP2A is essential for
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imparting ceramide responsiveness (Dobrowsky and Hannun, 1993;
Hannun, 1994).
but

not

by

CAPP is activated by short and long chain ceramides,
sphingomyelin,

sphingosine,

or

(Dobrowsky and Hannun, 1993; Hannun, 1994).

dihydroceramide
The specificities of

lipid mediators for CAPP activation in vitro closely matches their
specificities for various cellular activities of ceramide,

including

apoptosis (Dobrowsky and Hannun, 1993; Hannun, 1994).

Okadaic

acid, an inhibitor of serine/threonine protein phosphatases, inhibits
CAPP in vitro over a concentration range of 1-10 nM (Dobrowsky and
Hannun, 1993).

Okadaic acid has also been shown to inhibit the

effects of ceramide on c-myc downregulation as well as on growth
inhibition (Dobrowsky and Hannun, 1993).

These results provide

evidence

in

for

the

involvement

of

CAPP

ceramide-mediated

responses.
In summary, it appears that there may be several proteins
serving as direct or indirect targets for the action of ceramide.

To

further establish the roles of PLD and SMase in signal transduction,
the

relationship of their activation to that of members of the

mitogen-activated protein kinase (MAPK) family was explored ill
this thesis project.

Members of the MAPK family will be discussed
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below.

1-11.

Historical
Protein

Overview

of

Mitogen-Activated

Kinases

MAPK was first identified by Sturgill and Ray (1986) in 3T3-LI
adipocyte cells.

This enzyme was referred to as microtubule-

associated protein kinase 2 kinase, or MAP-2 kinase, because it
utilized MAP-2 as substrate in vitro.

These researchers found that

this kinase could phosphorylate and reactivate phosphatase-treated
ribosomal 86 kinase (RSK) (Sturgill and Ray, 1987).

RSK (pp 90 rsk ) is

a

serine/threonine

90

KDa

S6

kinase

that

is

activated

by

phosphorylation in response to mitogens and inactivated by protein
phosphatases 1 and 2A (Sturgill and Wu, 1991).

Subsequent

experiments confirmed the previous observations with the use of
insulin-activated MAP-2 kinase and inactive RSK from rat liver
(Gregory et al., 1989), and epidermal growth factor stimulated MAP2 kinase and inactive RSK from Swiss 3T3 cells (Gregory et al.,
1989; Ahn and Krebs, 1990). These studies implicated MAP-2 kinase

as a RSK kinase (Gregory et al., 1989; Ahn and Krebs, 1990).

Later,

two forms of MAP-2 kinase with molecular weights of 42 KDa and
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44 KDa were purified from fibroblasts (Cooper, 1989).

Due to the

wide substrate specificity of these kinases, the original

~me

of

MAP-2 kinase was later changed to MAPK for "mitogen-activated
protein

kinase"

(Boulton

et al.,

1990 Sturgill

and

Wu,

1991).

However, when the 42- and 44-KDa kinases were sequenced, the gene
products were referred to as ERKs (extracellular signal-regulated
kinases) (Boulton et al., 1990; Sturgill and Wu, 1991).

The two

isoforms are referred to as ERK1 and ERK2 (Boulton et al., 1990;
Sturgill

and

Wu,

phosphorylation

on

1991).

Activation

threonine

and

of

these

tyrosine

kinases

residues.

requires
However,

removal of a phosphate either from the threonine (by phosphatase
2A) or from the tyrosine (by CD45) results in inactivation of both
ERK1

and

ERK2

(Anderson

et al., 1990; Boulton et al., 1991).

Additional studies have confirmed the existence of several isoforms
that comprise the MAPK superfamily.

1-12.

Mitogen-Activated

Protein

Kinase

Family

Mitogen-activated protein kinases (MAPKs) comprise a family
of proline-directed serine/threonine protein kinases that have been
implicated in the control of a broad spectrum of biological and

40

cellular events (Nishida and Gotoh, 1993; Slenis, 1993).

MAPK

members are considered components of the intracellular regulatory
network that transduces extracellular cues to initiate intracellular
responses (Cano and Mahadevan, 1995).

These kinases are activated

by separate signaling cascades conserved through evolution.

Many

components of the pathways are expressed in yeast, nematodes,

Drosophila, and mammals (Cano and Mahadevan, 1995).

Three major

groups of MAPKs have been identified in mammalian cells.
1) the extracellular signal-regulated protein kinases,

These are
ERK1

and

ERK2, 2) the c-Jun NH2-terminal kinase or stress-activated protein
kinase, JNK/SAPK, and 3) p38 (HOG1) kinase (Cano and Mahadevan,
1995; Osborn and Chambers, 1996).

Each MAPK group has distinct

upstream activators and substrates (Cano and Mahadevan, 1995).
MAPK pathways

have

been

well

characterized

in

yeast.

Distinct MAPK cascades transduce signals that control pheromone
responses,

cell-wall

(Ammerer, 1994).

biosynthesis,

anQ osmosensitivity

in

yeast

Yeast MAPKs differ from mammalian MAPKs in

that they regulate separate phenomena; i.e., they seem not to be
activated

in

parallel

in

response

to

the

same

stimulus,

and

mutations in one cascade do not affect the phenomena regulated by
41

other stimuli (Ammerer,

19~4;

Blumer and Johnson, 1994).

In

/

i

contrast,

the

mammalian

MAPK

subtypes

can

be

activated

simultaneously via distinct parallel cascades in response to the
same stimulus (Cano and Mahadevan, 1995).

1-13.

Extrace lIu lar

Sig n ai-Related

Protei n

Ki nases

ERK1 (p44 ma pk) and ERK2 (p42 ma pk) are the predominant MAP
kinase isoforms expressed in most mammalian cells (Boulton et al.,
1991). These kinases 'are structurally very similar and are widely
expressed in various cells and tissues.

ERK1 and ERK2 are activated

by a number of extracellular stimuli, including growth factors (e.g.,
epidermal growth factor), cytokines, and some hormones that act
through G-protein-coupled receptors (Schlessinger, 1993; Blenis,
1993; Nishida and Gotoh, 1993; Marshall, 1994).

Phorbol ester tumor

promoters and other activators of protein kinase C can produce
dramatic stimulation of both ERK1 and ERK2 (Pelech et al., 1992).
ERKs are implicated in an array of cellular mitogenic events,
including cell cycle progression and the control of meiosis.
and ERK2 are inactive when dephosphorylated.

ERK1

Maximal activation is

achieved by phosphorylation of both a threonine and a tyrosine
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residue

(Ahn et al., 1992; Zheng and Guan, 1993; Denton and Tavare,

1995).

This activation is brought about by the dual-specificity MAP

kinase kinases, MEK1 and MEK2 (Ahn et al., 1992; Zheng and Guan,
1993; Denton and Tavare, 1995).

Downstream substrates regulated

by ERKs include transcription factors (e.g., Elk-1 and ATF2), protein
kinases (e.g., p90 rsk ), and several other targets (Davis, 1993).
p54 MAPK and p44 mpk are other isoforms of MAPK that have
been isolated, but characterized to a lesser degree than ERK1 and
ERK2.

pS4

MAPK is found to be stimulated in the

cycloheximide-treated rats (Pelech and Sanghera,
isoform is approximately 50%

livers of

1992).

This

homologous to rat ERK2 within its

catalytic domain (Pelech and Sanghera, 1992).

The p54 MAPK

phosphorylates MAP2 preferentially, and is sensitive to inhibition by
protein-tyrosine phosphatases as well as by the serine/threonine
phosphatase 2A (Seger and Krebs, 1995).
p44 m pk (MBP kinase) is a MAPK isoform that was originally
shown to be activated near the onset of germinal vesical breakdown
in maturing sea star oocytes (Pelech and Sanghera, 1992).

Protein

and nucleic acid sequencing studies have shown that p44 mpk shares
about 77%

amino acid identity with ERK2 and ERK1 (Pelech and
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Sanghera, 1992}.

p44 mpk is activated In vitro by

the

src-family

kinase p56 1ck (Pelech and Sanghera, 1992). Purified p44 m pk can
readily autophosphorylate on a serine residue with no detectable
tyrosine phosphorylation (Sanghera et al., 1991).

However, tyrosine

phosphorylation occurs during oocyte maturation and is required for
activation (Sang hera et al., 1991).

1-14.

c-JUN NH2-terminal

Kinases

JNKs, also termed stress-activated protein kinases (SAPKs),
comprise a subfamily of MAPKs that bind to and phosphorylate the
transcription factor c-Jun within its NH2-terminal domain (Hibi
al., 1993).

as ATF2
activity

et

JNKs also phosphorylate other transcription factors, such
and

Elk-1, and thereby augment their transcriptional

(Oerijard

et al.,

1994).

These kinases have been

characterized in a variety of mammalian· cells and tissues.

Two

major forms of JNK, JNK1 (46KOa) and JNK2 (55KDa), have been
characterized in human cells (Hibi et al., 1993).
and

55-KOa

phosphorylate

(JNK2)
the

kinases

are

amino-terminal

similarly
domains

The 46-KDa (JNK1)
regulated.
of

c-Jun,

Both
thereby

potentiating its trans-activation function (Hibi et al., 1993).
44

Both

forms require phosphorylation at threonine and tyrosine residues by
MAP kinase kinase 4 (MKK4/SEK1), a dual specificity kinase (Sanchez
et al., 1994; Davis, 1995; Derijard et al., 1995).

JNKs are activated

by a number of environmental stress-inducing stimuli; such as UV
light (Derijard
protein

et al., 1994), gamma radiation (Chen et al., 1996),

synthesis

(Westwick

inhibitors

(Kyriakis

et al.,

1994),

ceramide

et al., 1995), DNA-damaging drugs (Yu et al., 1996b),

chemopreventative

drugs

(Yu

et al.,

cytokines {Kyriakis et al., 1994}.

1996a),

and

inflammatory

In addition, JNK activity can also

be induced by mitogenic signals, including growth factors, oncogenic
Ras, CD40 ligation, and T-cell co-stimulation (Oerijard et al., 1994;
Minden et al., 1994; Su et al., 1994; Sakata et al., 1995; Berberich e t
a/., 1996; Chen et a/., 1996).

In T-cells, JNKs can be synergistically

activated by treatment with phorbol ester and calcium ionophore (Su
et al., 1994).

JNKs are implicated in both cell proliferation and

apoptotic cell death.

1-15.

p3S MAP Kinases
p38 MAPK is a homolog of the yeast HOG1 (high-osmolarity

glycerol response-1) kinase (Derijard et al., 1995).
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p38 is activated

by dual phosphorylation on tyrosine and threonine residues by MKK3
and MKK6 (Derijard et al., 1995; Han et al., 1996).

Activation of p38

MAPK is induced in response to lipopolysaccharide, hyperosmolarity
interleukin-1,

endotoxin,

TNF,

pro-inflammatory

cytokines,

shock, and DNA-damaging agents (Pandey et al., 1996).
p38

MAPK

can

occur through

c-Abl

protein

heat

Activation of

tyrosine

kinase-

dependent and -independent mechanisms (Pandey et al., 1996).

The

substrate specificity of p38 MAPK differs from ERK or JNK kinases.
p38 MAPK strongly phosphorylates transcription factor ATF2 (Post
and Brown, 1996), but does not phosphorylate cPLA2, c-Myc, or c-Jun
(Raingeaud et al., 1995).

p38 MAPK appears to play a role in

regulating inflammatory responses, including cytokine secretion and
apoptosis (Xia et al., 1995).

1.16.

MAPK Phosphorylation

Cascades

Activations of MAPKs occur through a series of sequential
protein-protein

interactions and phosphorylation

and Krebs, 1995).

reactions (Seger

Each MAPK cascade consists of a module of three

kinases: a MAPK kinase kinase (MEKK or MKK), which phosphorylates
and activates a dual-specificity MAPK kinase (MEK), which in turn
46

phosphorylates and activate a MAPK (Cobb and Goldsmith, 1995).
Members of the G-protein Ras superfamily are involved in the
activation of MAPK phosphorylation cascades (Marshall, 1995; Davis,
1993). In the case of the ERK cascade, Ras exchanges GDP (guanosine
diphosphate) for GTP (guanosine triphosphate) upon activation of a
Ras-specific

guanine-nucleotide

exchange

Downward, 1993; Vojtek and Cooper, 1995).

factor

(Viciana

and

In the GTP-bound state,

Ras then physically associates with the N-terminal region of Raf,
thereby

recruiting

this

serine/threonine

kinase

to

the

plasma

membrane, where it becomes activated by an unknown mechanism
(McCormick, 1994).

Raf in turn activates and phosphorylates MAPK

kinase (MEK), which ultimately leads to the activation of MAPK (ERK)
(Crews et al . , 1993).

Ras activation can also occur via protein-

tyrosine kinase receptors and G-protein-linked receptors. In this
case, autophosphorylation of the receptor protein-tyrosine kinases,
occunng as a consequence of ligand binding, provides docking sites
for Grb2.

Grb2 in turns interacts with the nucleotide exchange

factor mSOS to activate Ras (Davis, 1993; Marshall, 1995)
1-3).

(Figure

Activation of ERKs via G-protein-coupled receptors appears to

involve c-Src and Shc (Torres and Ye, 1996).
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Two member of the Rho family, Cdc42 and Rac, activate
members of the JNK phosphorylation cascade in the same way that
Ras

activates

Raf

(Cano

and

Mahadevan,

Cooper,1995; Coso et al., 1995).

1995;

Vojtek

and

It is believed that the activation

of MEKK by Cdc42 and Rac is mediated by PAK65 (Vojtek and Cooper,
1995).

PAK65

IS

a Cdc42- and Rac-binding protein (Vojtek and

Cooper, 1995).

The direct binding of PAK65 to Cdc42 and Rac

requires

GTP-bound

active

Cdc42

or

Rac,

and

stimulates the

catalytic activity of MEKK, -which then phosphorylates and activates
JNK kinase

(SEK), which

in turn phosphorylates and activates

JNK/SAPK (Figure 1-3) (Vojtek and Cooper, 1995).
The biological consequences and mechanism of activation of
the mammalian p38 MAPKs are poorly understood and are under
intense investigation.

These kinases are postulated to be regulated

similarly to the yeast HOG1 phosphorylation cascade.

A MAP kinase

kinase kinase (MAPKKK) referred to as apoptosis signal-regulating
kinase 1 (ASK1) can activate MKK3/MAPKK6, which in turn activates
the mammalian p38 MAPK and JNK (Ichijo et al., 1997) (Figure 1-3).
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FIGURE 1-3.
Mitogen-activated protein kinase signaling
pathways.
ERK, JNK, and p38 are MAP kinase family members that are
activated through parallel kinase cascades.
Interactions between
components of the various pathways may occur. ERKs are activated
by multiple G protein-linked receptors, growth factors, and phorbol
esters. JNKs are activated by growth factors and stress-related
responses. p38 MAPK is also regulated by stressful stimuli.
Activation of the kinases ultimately leads to the induction of
various transcription factors.
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1-17.

Goals and

Significance of Thesis Project

The overall goal of this thesis project was to investigate the
roles of PLD and SMase in signal transduction in T-Iymphocytes.
Previous and concurrent work in this laboratory used A7rS vascular
smooth muscle cells and Rat-1 fibroblasts to study the potential
role of agonist-induced PLD activation in ERK activation (Jones

al., 1994; Knoepp et at., 1996). This laboratory

et

also concurrently

studied the expression and regulation of PLD in yeast Saccharomyces

cerevisiae (Ella et aL, 1995).

Results from these studies showed

that the activation of PLD is not restricted
pathways,

and that

PLD

activation

to~

mitogenic signaling

is not sufficient for

ERK

activation. Nonetheless, phosphatidic acid has been proposed to
regulate Raf (Ghosh et al., 1996), and can induce proliferation in
some mammalian cell types (Flores et al., 1996).

With regard to

SMase, while ceramide appears to be involved in induction of
apoptosis, products of sphingomyelin metabolism can also induce
proliferation.

Ceramide

can activate ERKs in some cells (Olivera

ai, 1992) and JNKs in others (Westwick et al., 1995).

et

Thus, the role

of PLD and SMase require further clarifications.
It is now apparent that MAPKs can play very different roles in
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different cell types.

This is particulary apparent when fibroblasts

and T-Iymphocytes are compared.

ERK activation is required for

mitogenesis in fibroblasts, but can be involved in cell death in Tcells (Sansbury et al., submitted).
proliferation

of

T-cells

(Su

apoptosis in fibroblasts.

JNK activation is required for

et al.,

1994), but is involved in

Since the regulation of T-lymphocyte

proliferation and survival is of great importance with respect to
human health, the roles of lipid mediators in regulating MAPK
activities in T -cells is the focus of this thesis project.
Two T-Iymphocyte cell lines, Jurkat and EL4, were used in this
project.

These are IL-2 independent human and murine cell lines,

repectively.

Jurkat has been extensively used as a model to study

early events in T -lymphocyte activation and signal transduction.
EL4 has been used for many years to study signal transduction
leading to IL-2 expression.
When this project was initiated, very little was known about
the roles of PLD, SMase, and MAPKs, in T-cells.

Products of the PLD

and/or SMase reaction were proposed to participate in the activation
of MAPKs, JNKs, or other protein kinases.

Both ERKs and JNKs are

activated in T-cells in response to ligation of the T. . cell receptor.
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We therefore hypothesized that PLD and SMase are involved in MAPK
activation in T-Iymphocytes.
To address this hypothesis, Specific

Aim

I of this thesis

project characterizes the effects of phorbol ester (PMA), and the
antileukemic drug (Ara-C), on PLD and SMase activity in T -cells.
Reports from other laboratories had shown that Ara-C activates
SMase in some lymphoid cells (Strum et al., 1994).

We show that

treatment with phorbol ester stimulates acute activation of PLD in
Jurkat, but does not affect SMase activity in either EL4 or Jurkat
i

cells.

Ara-C does not affect PLD activity in either cell line, but

increases SMase activity in EL4 and Jurkat T-cells.

EL4 cells appear

to Jack PMA-stimulated PLD activity.
Specific Aim II of this thesis project explores the role of PLD
and SMase in activation of ERKs and JNKs in T-cells.

Activation of

ERKs is detected in EL4 and Jurkat T-cells in response to treatment
with phorbol esters. This activation does not however, appear to
depend on PLD activation.

Moreover, ERK activation is unaffected by

treatment with Ara-C or ceramides.

JNK activity is synergistically

increased in EL4 and Jurkat following treatment with phorbol esters
and calcium.

Ara-C induces delayed activation of JNKs in both EL4
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and Jurkat cells.
Specific Aim III of this thesis project examines mechanisms
underlying the activation of PLD and SMase.

We conclude that PMA-

induced activation of PLD is probably not due to translocation of PLD
or a direct interaction of PKCa with PLD
Our findings from this project suggest that PLD and SMase are
independently activated, and represent distinct signaling pathways
in T-cells.

The results of this study contribute to our understanding

of T-cell activation and death.
from

this

Moreover, the information obtained

study provides additional knowledge

regarding

basic

mechanisms involved in the activation of PLD, SMas9, ERKs, and JNKs
in T- lymphocytes.

53

CHAPTER 2

Effects of Phorbol Ester on Phospholipase D and
Mitogen-Activated

Protein

Lymphocyte
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Kinase
Cell

Activities

Lines

in

T-

2-1.

Introduction

Activation of both phospholipase D (PLD) and ERK mitogenactivated protein kinases are generally seen in response to phorbol
ester in non-lymphoid cells. PLD hydrolyzes phosphatidylcholine to
phosphatidic acid (PA), which can be converted to diglyceride and
other lipid mediators (Liscovitch, 1991).
via

a

ras/Raf-dependent pathway,

signals (Seger and Krebs, 1995).

ERKs, which are activated

generally mediate

mitogenic

The c-Jun N-terminal kinases

(JNKs) phosphorylate and activate c-Jun (Kyriakis et al. , 1994).
JNKs, which are synergistically activated in T-cells by phorbol ester
and calcium, have been linked to transcription of interleukin-2 (IL2) (Su et al., 1994).

Both ERKs and JNKs are activated in T-cells

following ligation of the T-cell receptor (TCR) (Su et al., 1994).
The mechanism of activation of PLD and its role in cellular
signalling

remain

to

be

established.

At

least two

forms

of

mammalian PLD exist (Hammond et al., 1995; Morris et al. , 1996).
Some PLDs can be activated by the GTP-binding proteins ADPribosylation factor (ARF) (Brown et al., 1993; Cockcroft et al., 1994;
Massenburg et al., 1994; Hammond et al. , 1995) or rho (Malcolm et
al. , 1994; Lambeth et al., 1995).
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Calcium-dependent activation of

PLD has also been reported (Olson et al., 1991; Gustavsson et al.,
1994).

Primary T-Iymphocytes and most T-cell lines do not exhibit

phorbol ester-activated PLD activity (Kinsky et al., 1989).

However,

in the Jurkat human leukemic cell line, PLD is activated by phorbol
ester or TCR ligation (Stewart et al., 1991).

Membrane PLD activity

is present in mouse thymus, but not in primary murine or human T
cells (Ella et al., 1994; Meier et al., 1994).

These observations

suggest that expression of PLD activity is regulated during T-cell
differentiation and transformation.
Activation of PLD has been proposed to play a role in mitogenic
signalling (Kondo et al., 1992).

PLD can be activated by growth

factors in a pathway downstream of PI-PLC and PKC (Lee et al.,
1994).

PA

can

be

converted

to

by

PA

phosphohydrolase, potentially supporting continued PKC activity.

PA

itself may act as a second messenger.

diacylglycerol

A role for PA in Raf

activation has been proposed (Ghosh et al., 1996).

The role of PA in

mitogenic responses is likely to vary between cell types (Jones e t

al., 1994).

The goal of this study was to examine the effects of

phorbol ester on PLO, ERK, and JNK activities in the Jurkat and EL4
T -lymphocyte cell lines.
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2-2.

Materials and Methods

Cell Culture

EL4 cell lines were originally provided by Dr. David Morris
(Univ. of Washington); phorbol ester-responsive wild-type (WT) cells
were used unless otherwise noted.

Phorbol ester-resistant variant

EL4 cells, in which PMA does not activate MAPKs, (Meier et al.,
1991) were used for some experiments.
were

obtained

from

Drs.

Sandra

Jurkat and HL-60 cells

Slivka

(Tanabe

Laboratories) and Khapil Shalla (MUSC).· respectively.

Research
Cells were

maintained in RPMI 1640 medium supplemented with 10%

fetal

bovine

and

serum

(UBI),

non-essential

amino

acids,

pen icill i n/strepto myci n.

Phospholipase 0 Assays

For PLD assays In intact cells, approximately 1x1 06 cells were
incubated overnight In complete culture medium (1 ml) containing 10
flCi/ml [3H]-palmitic acid (Dupont NEN).

Triplicate or quadruplicate

samples were used for each experimental condition.

Cells were

washed with ice-cold PBS and collected by low-speed centrifugation
(Seckman).

The cells were then incubated with and without 100 nM
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PMA (LC Laboratories) in the presence and absence of 0.5%

ethanol.

Ethanol was added immediately prior to addition of PMA.

At the

conclusion

of the incubation, cells were washed and ice-cold

methanol/6 N HCL (SO:2 v/v, 0.3 ml) was added.

This mixture was

transferred to a glass tube, and 0.5 ml chloroform was then added.
Phase separation was accomplished by the addition of 0.3 ml of 1M
NaC!.

The lower organic phase was recovered and dried under

nitrogen gas.

Cellular lipids were extracted from the cells with 30

JlI chloroform/methanol (90:10 v/v).

Dipalmitoyl-PA (Sigma) and

phosphatidylethanol (PEt) (Avanti Polar Lipids Corporation) were
added to each sample as chromatography standards.

Phospholipids

were separated using thin-layer chromatography developed with a
solvent mixture consisting of the upper phase of a mixture of ethyl
acetate/2,2 ,4-tri methylpentane/acetic

acid/wate r

v/v in ml) to which 1 ml acetic acid was added.

(90 :50 :20: 1 00,

Areas containing PA

and PEt, as well as the remainder of the lanes, were scraped and
transferred to vials for liquid scintillation spectrometry (Beckman).
The radioactivity contained in the PA and PEt bands is expressed as
a percent of the total radioactivity recovered .from each lane.
For PLD assays in broken cell preparations, cells were
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incubated in the absence and presence of 100 nM PMA or 10 U/ml PLD
from Streptomyces (Sigma).

Cytosolic and membrane extracts were

prepared as described for the ERK assay (see below).
activity was assessed
( B PC;

Membrane PLD

in vitro using BODIPV-phosphatidylcholine

2-decanoyl-1-(0-( 11-( 4 ,4-difl uo ro-5, 7 -d i methyl-4-bo ra -3a,

4 a-d i az a,s - i ndacene - 3 - pr opi ony I) ami no) undecy I )s n-g I yeer 0 - 3phospho-choline;
substrate.
~M

from

Molecular

Probes),

as

the

fluorescent

The reaction, containing 0.1 mM BPC, 150 mM NaCI, 200

octylglucoside, 25 mM MES (pH 6.0), 10 mM HEPES (pH 7.5), %mM

EGTA, 1mM EDT A, 40 mM f3-glycerophosphate {pH 7 .5}, 1mM DTT, and

1%

n-butanol in a final volume of 12.5

~I,

was initiated by addition

of 10 J.l9 of membrane protein and incubated for 30 minutes at 30 oC.
Cabbage PLD, used as a positive control, was from Sigma.

A

5-~1

aliquot of the reaction mixture was applied to a plastic-backed
silica gel G60 TLC plate without fluorescent indicator (Merck).

The

plate was developed using chloroform/methanol/water/acetic acid
(45:45:1 0:1,

v/v)

Results

were

imaged

using

a

Fluorlmager

(Molecular Dynamics) or GDS 5000 gel documentation and analysis
system (UVP Life Sciences).

For some experiments, results were
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FIGURE 2-5.
Immunoblots for PLD in EL4, Jurkat, and HL-60
cells.
Equal amounts of membrane protein from EL4 and Jurkat cells
were separated by SDS-PAGE and then immunoblotted with anti-PLD
antibody. The migration positions of molecular size markers are
shown o~ the right.

70

recognized a 120-kOa protein in Jurkat and HL-60.
visible

is

some

experiments.

The

A doublet was

immunoreactive

bands

were

predominantely localized to the membrane fraction (Figure 2-6).
The

mobility and localization

of

PMA treatment in Jurkat or HL-60.

these

bands

were

not altered by

These bands were not detected in

EL4.

Effects of PMA on ERK Activity
We have previously shown that ERKs are activated in response
to PMA in WT, but not variant, EL4 cells (Meier et al., 1991).

A

similar response has been reported for Jurkat cells (Nel et al., 1990;
Whitehurst et al., 1992; Marklund et al., 1993; Su et al., 1994). The
results shown in Figure 2-7 confirm that PMA stimulates ERK
activity, measured as MBP kinase activity, in both WT EL4 and Jurkat
cells.

MBP kinase activity was increased by 270 + 52%

by 181 + 24%

in EL4, and,

in Jurkat (mean + S.E.M., n. = 5 experiments for each

cell line), in response to PMA.

The lower fold activation in Jurkat

cells likely reflects the higher basal activity of MBP kinases other
than ERK in these cells; since MBP kinase activity in untreated cells
was 420/0 higher for Jurkat than for EL4 when measured in parallel in
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Anti-PLD

Membrane

120

kDa --. ......

FIGURE 2·6.
from Jurkat

~t_ ==::; _

Cytosol

..

Immunoblot for PLD in membrane and cytosol
cells.

Jurkat cells were incubated with or without 100 nM PMA for
the indicated times.
Equal amounts of membrane and cytosolic
protein were separated by 8DS-PAGE and then im'munoblotted with
anti-PLD antibody.
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FIGURE 2-7. Effects of phorbol ester on ERK activity in
Jurkat and EL4 cells.
WT EL4 (panel A) and Jurkat (panel 8) cells were incubated for
10 minutes in the absence and presence of 100 nM PMA and/or 2 JlM
ionomycin.
ERK activity was assessed in cytosolic extracts
Each data point
prepared from cells, using M8P as substrate.
represents the mean + S.D. of values obtained from duplicate
samples of cells.

73

the same experiment (n

=

4).

A combination of PMA and 2 J.lM

ionomycin did not produce a further increase In ERK activity in
either cell line.

Phosphorylation of ERKs is accompanied by a shift

in their electrophoretic mobility.

A major immunoreactive band of

approximately 42 kDa (ERK2) was detected in both EL4 and Jurkat
cells (Figure 2-8).

A 44 kDa band (ERK1) was also present, but is not

easily visualized in this particular immunoblot.

PMA treatment

resulted in a shift in the electrophoretic mobilities of ERK1
ERK2 in both EL4 and Jurkat cells.

and

These data indicate that PMA can

induce phosphorylation of ERKs in both EL4 and Jurkat cells.

Effects of Bacterial PLD on EL4 Cells
The data presented above suggest that generation of PA is not
required for ERK activation in T-cells.

Incubation of A7rS vascular

smooth

Streptomyces can increase

muscle cells with

PLD from

membrane PLD activity and elevate PA levels (Kondo et al., 1992;
Jones et al., 1994).

While the chemical composition and localization

of the PA generated has not been described, we have shown that
bacterial PLD remains associated with cell membranes in A7rS cells
(Jones et al., 1994).

Phosphatidylbutanol (PBt) was generated by
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EL4

c

Jurkat

c

p

p

FIGURE 2-8.
Immunoblot for ERK in EL4 and Jurkat cells.
WT EL4 and Jurkat cells were incubated in the absence or
presence of 100 nM PMA for 10 minutes. Whole cell extracts were
separated on SOS-PAGE and then subjected to immunoblotting for
ERKs using pan-ERK antibody.
Equal amounts of cellular protein
were loaded in each lane.
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membranes prepared from WT and variant EL4 cells incubated with
bacterial PLD (Figure 2-9).

The enhanced PLD activity is presumably

due to association of bacterial PLD with cell membranes.

The

results shown here also confirm that neither WT nor variant EL4
cells have PMA-stimulated PLD activity.
The

effects

of bacterial

PLD

on

intact

EL4

cells

were

Treatment of WT EL4 cells with bacterial PLD resulted in

examined.

a much greater elevation of PA than seen under the same conditions
for A7rS cells (Jones et al., 1994), suggesting that EL4 is less able
than A7rS to metabolize PLD reaction products.

However, while

incubation with bacterial PLD resulted in profound increases in PEt
and PA (Figure 2-10A), ERKs were not activated (Figure 2-108).
"

These data indicate that elevation of PA is not sufficient to induce
activation of ERKs in EL4 cells.

Effects of PMA on JNK Activity in EL4 and Jurkat Cells
In
activated

T-cells,
in

JNKs have been shown to

response to co-stimulation with

ionophore (Su et al., 1994).

be

synergistically

PMA and calcium

The mechanism underlying this co-

stimulation has not been delineated.

76

PMA alone has variable effects

EL4WT

EL4 variant

CPO

CPO
PBt

BPC
Iyso-BPC

Figure 2-9. PLD Activity in EL4 Membranes
WT and variant EL4 cells were incubated with no additions
("C"), with 100 nM PMA ("P"), or with 10 U/ml bacterial PLD ("0")
for 10 minutes.
PLO activity was assayed in membrane extracts
prepared from the cells, using the in vitro fluorescent assay. The
TLC separation of the reaction products is shown, with the
migration positions of the substrate (BPC), PA, Iyso-BPC, and
phosphatidylbutanol (PBt) indicated.
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FIGURE 2-10.
Effects of bacterial PLD on ERK activity in
EL4 cells.
In panel A, intact WT EL4 cells were incubated with 100 nM
PMA or 10 U/ml bacterial PLD for 30 minutes in the presence of 0.5%
ethanol.
Phosphatidylethanol (PEt) and phosphatidic acid (PA)
formation was assessed as described in the text. Each data point
represents the mean + S.D. of values obtained from triplicate
samples of cells. In panel B, WT EL4 cells were incubated with 100
nM PMA or 10U/ml bacterial PLD for 10 minutes. ERK activity was
assessed in cytosolic extracts prepared from cells, using MBP as
substrate. Each data point represents the mean + S.D. of values
obtained from duplicate samples of cells.
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on

JNK activity

in different cell

lines, with

a slight activation

previously reported for Jurkat cells (Su et al., 1994).

As shown in

Figure 2-11, PMA alone caused a slight activation of JNK in both
Jurkat and EL4 cells.

In both cell lines, JNK was synergistically

activated in response to a combination of PMA and ionomycin.
Treatment of Jurkat cells with exogenous bacterial PLD did not
activate JNK (Figure 2-12).

Thus, activation of PLD does not appear

to be required for JNK activation.

2.4.

Discussion
Phosphatidic acid, generated by the PLD reaction, has been

proposed to play a role in mitogenic signalling in mammalian cells.
,

Possible mechanisms for this effect include a direct effect of PA on
effector proteins (e.g., kinases or G-proteins), metabolism of PA to
DG (a PKC activator), or metabolism of PA to LPA.

LPA, a lipid

mediator binding to a G-protein-coupled receptor, is mitogenic for
some cell types (Moolenaar, 1995).
Proteins involved in the ERK activation cascade are proposed
targets for PA.
mitogenic

While activation of ERKs is an early event in

signalling,

it is

not

necessarily
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FIGURE 2-11.
Effects of PMA and ionomycin on JNK activity
in EL4 and Jurkat cells.
WT EL4 (upper panel) and Jurkat (lower panel) cells were
incubated in the absence and presence of 100 nM PMA and/or 2 ~M
ionomycin for 10 minutes. JNK activity was assessed in whole cell
extracts, using a solid-phase assay with GST-jun as substrate. Each
d~ta paint represents the mean ± S.D. of values obtained from
duplicate (Jurkat) or triplicate (EL4) samples of cells.
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FIGURE 2-12. Effects of bacterial PLD on JNK activity in
Jurkat.
Single aliquots of Jurkat cells were incubated in the absence
and presence of 100nM PMA, 2 J.1M ionomycin, and 10 U/ml bacterial
PLD for 10 minutes.
JNK activity was assessed in whole cell
extracts, using a solid-phase assay with GST-jun as substrate.
Similar results were obtained in two separate experiments.
81

proliferation (Jones et al., 1994; Lubinus et al., 1994).

In mature T-

lymphocytes, ERKs are activated both by TCR ligation and by IL-2,
but this activation is not required for proliferation (Alberola-lia e t
al., 1995).

Activation of JNK, which requires co-stimulation with

PMA and calcium, is necessary for induction of IL-2 synthesis

(Su et

al., 1994).

The results of our study confirm that PLD is expressed, and is
activated in response to phorbol ester, in the Jurkat cell line.
However, PLD activation and PLD activity were not observed in EL4
cells.

PLD activity was likewise not observed in human peripheral

T-cells, murine splenic T-cells, and a variety of murine T-cell lines
(Meier et al., 1994; Ella and Meier, unpublished data).
are consistent with

an earlier report that PLD

These results
activity is not

present in human peripheral T-Iymphocytes (Kinsky et al., 1989).
However, substantial PLD activity is present in membranes prepared
from mouse thymus (Ella et al., 1994).

Taken together, these results

suggest that expression of PLD activity ceases at some point during
T-cell

differentiation.
The number of isoforms of PLD expressed in mammalian cells

is unknown, with a 120-kDa form the first to be characterized at the
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molecular level

(Hammond

et al.,

A 120-kDa protein

1995).

recognized by an antibody to PLD was expressed in Jurkat and HL-60,
but not EL4.

These results suggest that the absence of PLD activity

in EL4 could be due to lack of expression of PLD.

However, since the

existence of at least one more mammalian isoform of PLD has been
reported (Hammond et al., 1995, Hammond et al., 1997),

it

is

possible that the other forms are expressed in T-cells, and that the
120-kOa enzyme is not responsible for PMA-stimulated PLD activity
in Jurkat and HL-60.

Alternatively, since the factors regulating PLD

activity have not been completely defined, the lack of PLD activity
in T -cells could be due to an absence of positive regulation.
The lack of correlation between PLD activity and ERK activity
\

is reminiscent of results obtained previously for the A7rS vascular
smooth muscle cell line (Jones et al., 1994).
proposed

It remains possible, as

(Ghosh et al., 1996), that PA generated by PLD can

contribute to Raf activation.

However, since ERKs are activated to

similiar extents in both EL4 and Jurkat, any contribution of PLD to
ERK activation in Jurkat cells is apparently minor.
We report here that PMA-stimulated JNK activity can be
detected in either the absence or presence of PMA-stimulated PLD
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activity.

The ability of PMA to synergistically activate JNK In EL4

cells, in which PLD is not activated, argues against a role for PLD in
JNK activation.
ionomycin

The observation that co-stimulation with PMA and

induces synergistic activation

of JNK,

but not PLD,

suggests that JNKs do not playa role in PLD activation.

It remains

possible that activation of PLD in response to a physiologic agonist
could contribute to other aspects of T-cell co-stimulation.

For

example, in some cell types, PA may serve as a source of DG to
sustain PKC activation (Martinson et al., 1990).

PA can also serve as

a substrate for the PLA2-mediated production of Iyso-PA (LPA)
(Moolenaar 1995).

LPA is mitogenic for fibroblasts (Van Carven et

al., 1989; Moolenaar, 1995), but has no effect on the proliferation of
Jurkat cells (Tigyi

et a/., 1994).

transduction

vary

may

Hence, the role of PLD in signal

between

cell

types

depending

on

the

expression of proteins that generate, metabolize and/or respond to
PA and LPA.
In

conclusion,

these

studies establish

that expression

of

ptiorbol ester-sensitive

PLD activity varies between different T-

lymphocyte cell lines.

Activation of PLD is not required for the

activations of either ERK or JNK seen in response to phorbol ester.
84

Other roles for PLD in the regulation of T-cell function remain open
for investigation.
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CHAPTER 3

Efffects

of

Sphingomyelinase

Mitogen-Activated

Protein

Lymphocyte
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Reaction
Kinase

Cell

Lines

Products

Activity

in

on
T-

3-1.

Introduction

Sphingomyelinase (SMase) can be activated in response to
extracellular 'signals, such as TNF-a,1 a,25-dihydroxyvitamin D3, and
complement (Hannun, 1994).

The SMase that is activated by

extracellular signals in mammalian cells appears to be a neutral,
Mg-dependent enzyme that is localized to the plasma membrane.

The

hydrolysis of sphingomyelin by SMase produces ceramide, a proposed
lipid mediator (Kolesnick, 1991).

Ceramide can effect the activity

of protein kinases (Liu et al., 1994) and phosphatases (Dobrowsky
and

Hannun,

1992),

interfere

with

protein-protein

interactions

(Kanety et al., 1996), and induce apoptosis (Obeid et al., 1993). For
example, in quiescent Swiss 3T3 fibroblasts, ceramide has been
shown

to

stimulate

[3 H]thymidine

incorporation

and

to

act

syngergistically with a wide variety of growth factors known to
induce

proliferation

In

these

cells

(Olivera

et al., 1992).

In

contrast, the ability of ceramide to induce apoptosis has been
demonstrated in both hemopoietic and nonhemopoietic cell lines,
including fibroblasts and fibrosarcoma cell lines (Hannun and Obeid,
1995).

Ceramide is considered by many researchers to be an

endogenous

mediator of

apoptosis
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that

may

modu late

signal

transduction through AP-1
and Obeid, 1995).
ester-induced

PLD

activation (Sawai et al., 1995; Hannun

Ceramide has also been shown to inhibit phorbolactivation

as

well

as

interfere

with

PKC-

mediated activation of PLD (Venable et al., 1996). The mechanism of
activation of neutral SMase has not been established, but may
involve activation of proteases (Pronk et al., 1996).
Consistent with its proposed role in programmed cell death,
ceramide has been shown to activate JNK kinases in some cell types
(Kyriakis

et al., 1994; Westwick et al., 1995; Welsh, 1996).

In

addition, ceramide has been reported to activate ERKs in HL-60 cells
(Raines et al., 1993).

ERKs are activated by growth factors and

other agonists via a ras-dependent protein phosphorylation cascade
involving Raf-1 and MEK (Seger and Krebs, 1995).
activated in response to both cytotoxic agents

JNKs can be
(Kyriakis et al.,

1994; Chen et al., 1996) and growth factors (Minden et al., 1995).
JNKs are activated downstream of the small GTP-binding protein rac
(Minden et al., 1995; Coso et al., 1995) via a phosphorylation cascade
involving PAK (8agrodia et al., 1995) and SEK (Moriguchi et al.,
1995).

The tyrosine kinase PYK2 can activate JNK via ras/rac

(Tokiwa et al., 1996) (Figure 3-1).
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The duration of JNK activation
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Plasma membrane

SMase
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?
Plasma membrane
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+

-Nucleus

c-jun, ATF2,

FIGURE 3-1.
Proposed mechanism for SMase activation
leading to JNK signaling.
The antileukemic drug, Ara-C activates a neutral SMase in the
plasma membrane resulting in hydrolysis of sphingomyelin (8M) to
ceramide and phosphocholine. It is unknown whether ceramide
indirectly activates JNK (e.g., via rac,cdc42), or directly activates
kinases upstream of JNKs. JNK activation leads to activation of the
transcription factors c-jun and ATF2.
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may be important with respect to the signal transduced, since
physiologic

stimuli

typically

induce

transient

activation,

while

gamma radiation induces persistent activation (Chen et al., 1996).
In

T-Iymphocytes,

JNKs

are

synergistically

activated

in

response to a combination of phorbol ester and ionophore, or in
response to ligation of the T-cell receptor (Su et al., 1994).

These

stimuli result in expression of interleukin-2 (IL-2) and stimulation
of T-cell proliferation.

Although JNK activation appears to be most

important in the regulation of IL-2 expression, both ERKs and JNKs·
are

activated

by

T-cell

ligation

"

in

T-cells

(Su

et al.,

1994).

Recently, it was shown that T-cell receptor-mediated activation of
both ERKs and JNKs is blocked in anergic T cells (Fields et al., 1996;
Li et al., 1996).

In non-lymphocytic cells,

ERKs and JNKs are

proposed to play opposing roles in the regulation of apoptosis, with
JNK activation inducing cell death and ERK activation opposing it
(Xia et al., 1995).
activation,

but

However the existing literature suggests that JNK
not

ERK

activation,

is

required

for

T-cell

proliferation.
The studies cited above suggested that ceramide may activate
members of the MAPK family. We examined whether this was the
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case

in

T-cells.

Specifically,

this

study

addresses

whether

ceramide is a second messenger inducing JNK or ERK activation in Tcell lines.
Several strategies have been used to elevate ceramide levels
in mammalian cells.

As discussed earlier, several cytokines can

increase ceramide in intact cells (e.g., TNFa, IL-1).

However, a

response to these agonists is dependent on expression of the
appropriate receptor in the cells of interest (Hannun and Obeid,
1995).

Long-chain

ceramides,

similar

to

those

produced

endogenously, are not cell-permeable and generally do not mimic the
effects of agonists on intact cells.

Short-chain ceramides have been

widely used to mimic the actions of agonists that increase ceramide
levels.

C2-

and

C6-ceramide

are

cell-permeable,

short-chain

ceramides shown to elicit responses in a wide variety of cell types.
Finally, exogenous bacterial SMase has been reported to elevate
ceramide levels in intact cells and to induce signal transduction
(Olivera at al., 1992).
Ara-C has been reported to induce acute activation of SMase in
HL-60 cells (Strum at al., 1994) and in other cell types (L. Daniels,personal communication).

Ceramide can induce apoptosis in HL-60
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via induction of AP-1, which contains c-Jun (Sawai et al. , 1995).
fibroblasts,

Ara-C activates JNKs via the tyrosine kinase c-Abl

(Kharbanda et al., 1995).
events

In

The role of such early signal transduction

in the cytotoxic response to Ara-C have not yet been

establ ished.
Ara-C, an anti-leukemic drug (Kharbanda et al., 1994; Strum e t
al., 1994), is a nucleoside analog that is transported into the cell by
a nucleoside transporter and is then sequentially phosphorylated to
Ara-CTP:

Ara-C

.. Ara-CMP

lit

Ara-CDP

.. Ara-CTP

The cytotoxic metabolite of Ara-C, Ara-CTP, is incorporated into
DNA, resulting in slowing of chain elongation and induction of strand
breakage (Crisp et al., 1996). Ara-C causes DNA fragmentation and
endonucleolytic DNA cleavage, which is a hallmark of apoptosis
{Kufe et al., 1984}.
DNA

Ara-CTP also acts as a competitive inhibitor of

polymerase.

triphosphates

(dNTPs)

Accumulation
in

of

deoxyribonucleoside

response to Ara-C

is thought to

be

responsible for disruption of DNA synthesis in susceptible leukemia
cells

(Crisp et al., 1996).

Since Ara-C appeared to be a general
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activator of SMase, and was known to be cytotoxic for In Tlymphocytes, it was used as a model stimulus in our studies.

3-2.

Methods

Cell Culture and Incubations
Jurkat cells and wild-type EL4 cells (Gause et al. , 1993) were
orig inally provided by Drs. S. Slivka (Tanabe Research Laboratories)
and D. Morris (University of Washington), respectively.
maintained in RPMI 1640 supplemented with 10 %

Cells were

fetal bovine serum

r

(UBI), non-essential amino acids, and penicillin/streptomycin. Cells
were incubated with the desired agents (100 nM PMA, {LC Services},
100 JlM Ara-C {Sigma}, 5 JlM ceramide {Sigma}, or 10 U/ml bacterial
SMase, {Sigma}) in culture medium at 37 o C, washed with ice-cold
phosphate-buffered saline (PBS), resuspended in lysis buffer (20 mM
HEPES {pH 7.S}, 80 mM B-glycerophosphate, 10 mM EGTA, 2 mM EDTA,
2 mM DTT), sonicated, and sedimented by centrifugation (Seckman)
at 100,000 x g for 20 minutes at 4 o C.

The supernatant (cytosol) and

pellet

ERK

(membranes)

respectively.

were

used

for

and

SMase

assays,

Extracts prepared in whole-cell lysis buffer (20 mM

Tris {pH 7.4}, 137 mM NaCI, 25 mM B-glycerophosphate, 2 mM sodium
93

pyrophosphate, 2 mM EDTA, 1 mM Na3V04, 1%

Triton X-100, 100/0

glycerol, 1 mM PMSF, 5 Jlg/ml aprotinin, 5 Jlg/ml leupeptin, 2 mM
benzamidine, 0.5 mM DTT} were sedimented by centrifugation at
100,000 x 9 for 30 minutes at 4 o C.

The supernatant was used for

JNK assays.

SMase Assay
SMase

activity

sph ingomyel i n

was

assayed

in

vitro

using

BOOIPY-

(N-( 4,4-difluoro-5, 7 -di methyl-4-bo ra-3a ,4a-diaza-

s-indacene-3-pentanoyl}sphingosyl-phosphocholine, BSM, Molecular
Probes, catalog #0-3522).
Probes, Inc.

BOOIPY is a trademark of Molecular

The assay was performed as previously described for

phospholip-ase D (refer to Chapter 2), except that magnesium was
included.

The reaction mixture (12.5 JlI) contained 10 J1,g membrane

protein, 100 J..LM 8SM, 150 mM NaCI, 25 mM HEPES (pH 7.5), 5 mM
EGTA,

1

mM

EDTA,

40

mM

octylglucoside, and 3 mM MgCI2.

B-glycerophosphate,

200

J..L M

The concentration of 3mM MgCI2

was determined to be optimal for measurement of SMase activity in
Jurkat membranes (Ella and Meier, unpublished observations).
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88M

was solubilized prior to each assay by brief sonication in buffered
solution (0.5 mM octylglucoside, 400 mM NaGI, 66 mM MES {pH 6.0}).
Reactions were incubated for 60 minutes at 30oG.

A 5-JlI aliquot

was applied to silica gel G60 thin-layer chromatography plates
(Merck) and developed in chloroform/methanol/water/ acetic acid

•

(45:45:10:2).
Fluorlmager
densitometer
calculated
loading.

Results were imaged and/or quantitated
(Molecular
(Helena

Dynamics)
Laboratories).

or

scanning
Product

as a percerit of total fluorescence to

using a

fluorescence
formation

was

normalize for

Protein concentrations were determined using Coomassie

reagent (Pierce).

Protein Kinase Assays
The methods used to assess ERK and JNK activity were
described in Chapter 2.

3-3.

Results

Characterization of SMase Activity
A fluorescent assay was used to characterize SMase activity
in cell membranes.

This assay has been used to characterize a yeast
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SMase (Ella et al., 1997).

The substrate used, BSM, has a BODIPY

fluorophore conjugated to the fatty acid at the 2-position of the
sphingoid backbone.

Similarly substituted sphingolipids can serve

as substrates for neutral SMase, but not for lysosomal acidic SMase
(Levade et al., 1991).

In other words, acid SMases cannot hydrolyze

sphingomyelins with a bulky substituent at the 2-position.
As shown in Figure 3-2, membranes from Jurkat and EL4 cells
convert 8SM to BODIPY-ceramide in the presence of magnesium.
SMase activity was

present in

cytosol.

Similar results

No
were

obtained in the absence and presence of dithiothreitol, an inhibitor
of acid SMase (Maruyama and Arima, 1989) (data not shown).

The pH

optimum was 7.5 for Jurkat membranes (data not shown).

These

data indicate that the in vitro assay detects a neutral

SMase

activity in a T-cell line.

Effects of Ara-C and PMA on SMase Activity
The efects of agonists on SMase activity in T-Iymphocytes had
not been previously studied.
membrane

SMase

activity

The effects of Ara-C and PMA on
were

therefore

examined.

consistently induced an increase in SMase activity.
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Ara-C

In Jurkat cells,

Sample:

S-cer

SSM

EL4

EL4

Jurkat

+

+

Jurkat

SMase
+
8-cer

8SM

origin

FIGURE 3-2.
SMase activity in Jurkat and EL4 cells.
SMase activity was assessed in membranes using an in vitro
fluorescent assay with BSM as substrate in the absence and presence
of 3mM MgCI2. The thin-layer chromatography plate was imaged by a
Fluorlmager (printed w1th reverse contrast). BSM, BODIPY-ceramide
(B-cer), and bacterial SMase incubated with BSM, were
chromatographed as standards. MgCI2 did not alter the amount of Bcer present in the absence of membranes or SMase (data not shown).
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FIGURE 3-3.
Effects of Ara-C on SMase activity in Jurkat
and EL4 cells.
SMase activity was measured in vitro. Panel A: Cells were
incubated for the indicated times with 100 JlM Ara-C.
Ceramide
production is expressed as percent of total fluorescence. Panel B:
Cells were incubated for 10 minutes with 100 JlM Ara-C or 100 nM
PMA. Ceramide production, as percent of the value for untreated
control cells, is the mean + S.E.M. from six (Jurkat) or three (EL4)
independent experiments.
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FIGURE 3-4.
Effects of Ara-C on SMase activity in Jurkat.
Membrane SMase was measured in vitro using a fluorescent
assay. Single aliquots of Jurkat cells were incubated for 10 minutes
Ceramide
with 10 JlM Ara-C, 100 J.!M Ara-C, or 100 nM PMA.
production is expressed as percent of total fluorescence. Each data
point represents the mean + S.D. of values obtained from duplicate
samples of cells.
100

200

....-...

-

(I)~
"0'"
-- C

~

8

'--...
(1)0

100

Otfl.
'-'"

o
Control

PMA

lonomycin

Ara-C

FIGURE 3-5.
Effects of PMA and ionomycin on SMase
activity in Jurkat.
Membrane SMase activity was measured in vitro using a
fluorescent assay.
Single aliquots of Jurkat cells were incubated
for 10 minutes with 100 nM PMA, 2 11M ionomycin, or 100 11M Ara-C.
Ceramide production, as percent of the value for untreated control
cells, is the mean + S.E.M. from three independent experiments.
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labelled

lipids was

effective

products (data not shown).

in

resolving

ceramide from

other

Unfortunately, no increase in cerarnide

levels was detected in these experiments.

Since our major goal was

to determine whether ceramide acts directly as a second messenger
to induce MAPK activation, measurement of ceramide accumulation
was not further pursued.

The following sections describe more

pharmacologic approaches to address the role of ceramide in T-cells.

Effects of Ara-C and PMA on ERK and JNK Activities
The effects of Ara-C, PMA, and other agents on ERK activity
were examined.

PMA activated ERKs in Jurkat in 10 minutes, while

Ara-C had no effect (Figure 3-6A).

C2-ceramide, a cell-permeable

derivative (Gomez-Munoz et al., 1994), did not affect ERK activity.
Similar results were obtained with EL4 (Figure 3-68), in which PMA
activates ERKs (Chapter 2).
JNKs were synergistically activated in Jurkat (Figure 3-7 A)
and EL4 cells at 10 minutes by a combination of PMA and ionomycin,
as previously reported (Su et al., 1994; Bradshaw et al., 1996).

PMA

alone slightly activated JNKs, while ionomycin, Ara-C, C2-ceramide
(5 and 50 JlM), and crude ceramide neither activated JNKs at 10
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FIG·URE3 .. 6.
Effects · of Ara;'C and C2-ceramide ' on
activity in Jurkat and E'L4 cells.

ERK

In the same experiment, both cell types were incubated for 10
minutes with 100 nM PMA, 100 JlM Ara-C, or 5 JlM C2-ceramide.
Results from JurkatceUs are shown fn panel A, and from EL4 cell's
in panel B.CytosolicERK activity is the mean + S.D. of values
obtained from duplicate aliquots of cells.
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activity in Jurkat cells.
In panel A, Jurkat cells were incubated for 10 niinuteswith
100 nM PMA, 2 J.!M ionomycin,PMA +ionomycin, 100 JlM Ara-C, Ara-C
+ PMA, 5 JlM C2-ceramide, C2-ceramide+ PMA, 5 JlM ceramide, or
ceramide + PMA. JNK activity in whole cell extracts is expressed as
the mean + S.D. from duplicate aliquots of cells. In panel B, single
aliquots of Jurkat cells were incubated for 10 minutes with 100 nM
PMA, PMA + lonomycin, 10 U/ml bacterial SMase, or 5 J-lM ceramide1-phosphate. Similiar results were obtained in two separate
experiments.
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minutes (Figure 3-7A) nor affected the response to PMA (Figure 37 A). Ceramide-1-phosphate (5 JlM) and SMase from S. aureus (10
U/ml) likewise did not activate JNK at 10 minutes (Figure 3-78).
Higher doses of ceramides did not affect JNK activity (data not
shown).
Since

cytotoxic

agents

can

cause

a slowly-induced

and

persistent stimulation of JNKs (Park et al., 1996), the effects of
more prolonged incubations with Ara-C were examined.

As shown in

Figure 3-8A, JNK activation was observed when Jurkat cells were
incubated for longer

times

with

Ara-C.

JNK activation was

apparent by 90 minutes, and persisted for at least 120 minutes.
Similar results were obtained in EL4, in which JNK activation was
observed only after 120 minutes (Figure 3-88).
Ara-C did not activate ERKs at 10-120 minutes In Jurkat
(Figure 3-9) or EL4 (data not shown).
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Effects of prolonged treatment with Ara-C on
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Effects of prolonged treatment with Ara-C on
ERK activity in Jurkat cells.
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3-4.

Discussion
We have examined the potential role of SMase activation in

regulating the activities of the ERK and JNK kinases in two T-cell
lines. We show for the first time that Jurkat and EL4 cells express a
membrane-localized neutral SMase.

We also show that SMase

activity is increased in membranes prepared from Ara-C-treated
cells.

One previous report indicated that the activated state of

neutral SMase could be preserved in a broken-cell preparation
(Strum et a/., 1994).

·With the exception of divalent cations, we and
;

others have not identified factors· that activate neutral SMase in
membrane preparations.

A role for proteases in SMase activation

has been proposed on the basis of intact cell studies (Wright et a/.,
1996).

Until suitable molecular pr'obes are developed for neutral

SMase, it will not be possible to determine whether the enzyme is
activated

by

covalent

modification

(e.g.,

phosphorylation),

translocation, proteolysis, or via protein-protein interactions.
Ceramide does not appear to activate the ERK cascade in Jurkat
or EL4 cells.

These results contrast with those observed in one

study of HL-60 cells, in which ceramide induced ERK activation
(Raines et al., 1993).

However, in another study, ceramide inhibited
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ERK activity in HL-60 cells (Westwick et al., 1995). Since ERKs can
be activated by PKC activators in both Jurkat and EL4 cells (Chapter
2), the

lack of effect of Ara-C suggests that Ara-C does not

significantly stimulate protein kinase C-mediated pathways in these
T-cell lines.

We were unable to detect any significant inhibitory

effect of Ara-C on PMA-induced ERK or JNK activation in this study.
JNKs were not activated at early time points after Ara-C
addition, when SMase was activated, but were activated in response
-to more prolonged treatment with Ara-C.

This time course does not

correlate with the acute (10-minute) activation of SMase by Ara-C
in this and a previous study (Strum et al., 1994).

Since SMase

activity remains elevated for at least one hour, it is possible that
accumulation of ceramide (or its metabolites) is a direct signal for
JNK activation.

However, we did not detect JNK activation following

a 10-minute incubation with cell-permeable ceramides.

Bacterial

SMase induced acute JNK activation in hepatoma cells (Kyriakis et
al., 1994) and HL-60 cells (Westwick et a/., 1995).

Interpretation

of these responses may be complicated by the· fact that bacterial
SMase preparations can contain additional phospholipase activities
(Ella and Meier, unpublished observations).
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Ceramide induces c-Jun

within one hour in HL-60 cells (Sawai et al., 1995), an effect that
could be consistent with a delayed time course ofJNK activation.
Taken together, these results suggest that ceramide can induce
long-term effects on mammalian cells.
potential

physiologic

importance,

Such effects, though of

make

it

more

difficult

to

determine whether ceramide is truly a "second messenger."
The role of SMase activation in the induction of apoptosis by
Ara-C in cells of hematopoietic origin remains unclear.
JNKs

can

be

activated

by

"stressful" cytotoxic

Although

stimuli,

their

;

positive

involvement

in

T-cell

proliferation

(Su

suggests that their roles can vary between cell types.

et al.,

1994)

The balance

of JNK and ERK activities can determine the final cellular response
(Xia et al., 1995).
activated.

In T-cell activation, both ERKs and JNKs are

In contrast, Ara-C activates only JNKs in Jurkat and EL4

cells (this study) and in HL-60 cells (Westwick et al., 1995).
kinetics of the response may also be important.

The

Lethal irradiation

induces a prolonged activation of JNK that is not detected until after
one hour (Su et aI., 1994).

In fibroblasts, Ara-C activates JNKs only

after two hours (Kharbanda et al., 1995).

If activation of JNKs leads

to apoptosis in the absence of ERK activation, perhaps it is
11 0

necessary that this

response

be

initiated

response to a persistent cytotoxic insult).

slowly

(i.e.,

only

in

Finally, apoptosis can be

induced

by withdrawal

of positive

(Ishizaki

et al. , 1995).

Both ERKs and JNKs are activated by co-

stimulation of T-cells.

signals for cell

proliferation

Thus, activation of JNK in the absence of

ERK activation may be an important aspect of the action of cytotoxic
agents that activate SMase in T-cells.
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CHAPTER 4

Expression and Regulation of Phospholipase 0
Activity in Mammalian Cell Lines

....
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4-1.

Introduction
Phospholipase D (PLD), which catalyzes the hydrolysis of

phosphatidylcholine (PC) to phosphatidic acid {PAl, is proposed to
play an important role in signal transduction for many types of cells.
PLD is activated in mammalian cells in response to growth factors,
agonists that activate phosphatidylinositol-specific
PLCs), and phorbol esters (Exton, 1990).
forms of PLD exist.

PLCs

(PIP2-

It is not clear how many

Although cytosolic forms have been described,

the regulated forms appear to be membrane-bound.

The mechanism

l

of activation of PLD may vary between isoforms.

Several factors

have been implicated in the regulation of PLD activity, including
calcium, PKCs, protein-tyrosine kinases, and GTP-binding proteins
",

{Exton, 1994}.

The GTP-binding proteins ARF and Rho activate some

forms of PLD (Exton et al., 1992; Cockcroft, 1992; Bowman et al. ,

1993; Liscovitch et al. , 1994; Siddiqui et al. , 1995;
1995).

Brown ef al.,

P1P2 acts as a cofactor for various forms of PLD, including

ARF-dependent forms.

PLDs may be synergistically regulated by

PKC, ARF, and Rho (Ohguchi et al., 1996; Singer et al., 1996).
PLD can be activated by PKC via mechanisms that mayor may
not involve protein phosphorylation.
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Olson and co-workers (1991)

have reported that PMA-induced PLD activation is dependent on ATP

in the neutrophil cell-free

system~

Additional studies have shown

that the effect of ATP on PKC-mediated PLD activation is mediated
by phosphorylation in human neutrophils (Lopez et al.,

1995).

Membrane-bound PLD can be activated by PKC in a phosphorylationindependent

mechanism

(Conricode et al., 1992).

in

Chinese

hamster

lung

fibroblasts

In these cells, the activation of PLD by PKC

was observed in the absence of ATP, suggesting that PKC may
activate PLD by an allosteric mechanism without ATP-dependent
phosphorylation (Conricode et alt.,

1992).

In

liver

membranes,

stimulation of PLD by PKC likewise does not require ATP (Lopez
al., 1995).

et

In HL-60 cells, Ohguchi and co-workers (1995) have

shown that PKC-mediated PLD aotivation is suppressed by R031-

8425, a potent PKC inhibitor.

These studies imply that a novel,

phosphorylation-independent mechanism exists for PLD activation by
PKC (Morris

et a/.,

1996).

Recently, specific PKC isozymes have been implicated in the
regulation of PLD.

In HL-60 cells, PLD activity was found in

partially-purified PKC fractions containing a, (31, 1311, and "{ isozymes

'.
(Ohguchi et al., 1996). PKCa and

-~,
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but not -1, were able to activate

membrane-bound PLD (Ohguchi et al., 1996).

Among these iSQzymes,

PKCa was most effective in activating PLD.

One report showed that

Rho was

required for activation of PLO by G-protein-coupled

receptors, but not by PKC (Hess sf al., 1997).

However, other

investigators have found that PKC acts additively or synergistically
with Rho (Singer e f al., 1996).

Thus, the mechanism by which PKC

activates PLD remains to be established.
Our

labor~tory

has raised an antibody against a 12-amino acid

portion of the yeast PLD sequence that is conserved between plants
i

and yeast.

Ten amino acids (83%) of this sequence are conserved in

human PLD1 a and 1b, (Hammond ef al., 1997)..

This antibody

recognizes yeast and plant PLDs, as well as a 120-kOa band in a
variety of mammalian cell lines.

The 120-kOa band is not observed

in EL4 cells, which lack significant PLD activity, but is observed in
Jurkat cells, which express PLD activity (refer to Chapter 2).

The

120 kOa band is present mainly in membranes, and does not
translocate from cytosol to membranes upon treatment of Jurkat
cells with PMA.

A 50 kDa band has also been observed ih both

cytosol and' membranes from a variety of cell lines.

be an additional isoform of PLD.

This band may

Additional bands of approximately
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90- and 95- kDa are seen in some cells.
hPLD1 can be activated in vitro by ARF, P1P2, and PKCa (Morris
Whether this is the major form of PLD regulated by

at af., 1996).

agonists is not clear.
activity of hPLD1

The mechanism by which PKCa regulates the
has not been established.

localization of hPLD1 has not been reported.

The subcellular

Moreover, as discussed

in Chapter 1, there may be more than one form of agonist-activated
PLD.

This chapter describes studies designed to address some of

these issues.

I

In our in

vitro assays,

agonist-stimulated

PLD activity is

detected in the absence of added GTP-binding proteins, guanine
nucleotides, or ATP.

There are at least two possible explanations

for the observed retention of agonist stimulation.

First, membrane

PLD activity may be increased due to translocation of inactive PLD
to the membrane, where it may be activated by binding to membrane
constituents.

Second, PLD already localized to the membrane may be

activated by protein-protein (e.g.,
P L 0 - PIP 2)

interactions

PLD-P~C)

or protein-lipid (e.g.,

that are preserved

in

the

membrane

preparation used for the in vitro assay.
In this study, we explore the use of the anti-PLD antibody to
116

examine localization and regulation of agonist-activated PLDs in
Jurkat T-cells and in PC-3 and LNCaP human prostate cancer cells.
The

potential

examined.

for

regulation

of

PLD

by phosphorylation was

The potential interaction of PLDs with PKCa was also

explored.

4-2.

Materials and Methods

Cell Culture
Jurkat cells were maintained as described in Chapter 2.
f

PC-3

and LNCaP cells, originally obtained from the American Type Culture
Collection, were maintained in F12K medium and RPMI medium,
respectively, supplemented with
Biologicals).

Cells

were

10%

>",

incubated

fetal calf serum (Atlanta
with

100

nM

PMA

(LC

Laboratories) in culture medium at 37 oC, washed with ice-cold PBS,
resuspended

in

lysis

buffer

(20

mM

HEPES,

80

mM

B-glycerophosphate, 10 mM EGTA, 2 mM EDTA, 2 mM OTT, {pH 7.5}),
sonicated, and sedimented by centrifugation at 100,000 x 9 for 30
minutes at 4oC.

The supernatant (cytosol) and pellet (membranes)

were used for PLD assays .
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Phospholipase 0 Assays

For PLD assays in intact cells, cells were incubated overnight
in complete culture medium (1 ml) containing 10 J.1Ci [3H]-palmitic
acid (Dupont NEN). Washed cells were incubated with and without

100 nM PMA (LC Laboratories) in the presence and absence of 0.50/0
ethanol.

Triplicate or quadruplicate samp1es were used for each

experimental condition.
cells

with

Cellular· lipids were extracted from the

chloroform/methanol

and

separated

chromatography as described in Chapter 2.
r

by

thin

layer

Spots containing

phosphatidylethanol (PEt) and phosphatidic acid (PA) were collected
for liquid scintillation spectrometry.

Results are presented for each

product as a percent of the total rC\dioactivity recovered.
For PLD assays in broken cell preparations, cells were
incubated in the absence and presence of 100 nM PMA. Cytosolic and
membrane extracts were prepared as described in Chapter 2.
Membrane PLD activity was assessed in vitro using a fluorescent
substrate, BPC (Molecular Probes).
membrane protein.

Each reaction utilized 10 J.1g of

The products were separated on silica gel G60

TLC plates (Merck) and imaged using a Fluorlmager (Molecular
Dynamics).

Results were quantitated using a fluorescent scanning
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densitometer (Helena Laboratories).

Data are quantitated as a

percent of the total fluorescent signal recovered from each sample.

Immunoblotting
For the immunoblotting experiments, whole cell extracts were
prepared.

Cells were incubated with and without 100 nM PMA and

)

incubated in lysis buffer (20 mM HEPES {pH 7.4}, 1% Triton X-100, 50
mM NaGI, 1 mM EGTA, 5 mM B-glycerophosphate, 30 mM sodium
pyrophosphate,

1 00 J.1g

soc;lium

phenylmethylsulfonyl fluoride, 10
leupeptin.

orthovanadate,

1l9/ml

aprotinin, and 10

1

mM
J,lg I m I

The Iysates were sedimented by centrifugation at 10,000

x 9 for 10 minutes at 40C to remove debris. Supernatant proteins
were separated by SOS-PAGE on 10 or 12.5%

Laemmli gels and

transferred to nitrocellulose membranes (Micron Separations, Inc).
Primary antibodies to PLD (polyclonal) were prepared by immunizing
a rabbit with the peptide CIIGSANINERS linked to keyhole limpet
hemocyanin.
yeast

PLD1

The peptide represents amino acids 1107-1118 of
(Ella et a/.,

1996),

corresponding

(with

two

substitutions) to residues 907-918 of human PLD1 (Hammond et al.,
1995). Anti-PKCa (monoclonal) was obtained from Transduction
119

Laboratories.
immunoblots

After
were

incubation

developed

with

using

primary

gold-labelled

antibodies,
secondary

antibodies with silver enhancement (Amersham).

Immunoprecipitation
Whole cell extracts were prepared as described above for
immunoblotting.

Antibodies to PKCa

extracts for 2.5 hours at 40C with mixing.

were' incubated with the
Protein

A~agarose

(Santa

Cruz Biotechnology) was then added; the incubation was continued
for 1 hour.

The agarose beads were collected by centrifigation,

washed several times with buffer, and then boiled in Laemmli
sample

buffer.

For

denaturing

conditions,

anti-PKCa

immunoprecipitations were carried out as described above, except
that cells were extracted with boiling solution (1 %

Hel pH 7.4) and then sonicated.

SDS/10 mM Tris

Proteins in the immunoprecipitate

were subjected to immunoblotting as described above.
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4-3.

Results

PLD in Jurkat cells
In chapter 2, we showed that PLD is activated in response to
PMA in Jurkat cells (Chapter 2).

We examined the expression of PLD,

using a newly-developed antibody against PLD.

We were able to

detect a 120-kDa immunoreactive protein in Jurkat cells (Chapter
2).

This band, which may correspond to human PLD1 and/or its

splice variant (Hammond et al., 1997), was predominantly localized
to the membrane fraction.

We were also able to detect 90-95-kDa

and 50-KDa bands in the cytosol and membrane fractions of Jurkat
(data not shown).

None of the bands were translocated or showed

mobility shifts in response to treatment of cells with PMA.
Additional experiments were performed to determine whether
activation of PLD occurs as a result of protein phosphorylation.
Membranes from control and PMA-treated cells were incubated in
the absence and presence of alkaline phosphatase.

As shown in

Figure 4-1, PMA-induced PLD activity was substantially decreased
in the presence of alkaline phosphatase.

Similiar results were also

seen for Ara-C-induced SMase activity (data not shown).

As a

positive control for phosphatase activity under the conditions used,
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t

s

I

f

A

alk lin
r 10
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h s h

immunoblots were performed using anti-ERK antibody (data not
shown).

Reversal of the PMA-induced ERK mobility shift indicated

that ERKs were dephosphorylated by alkaline phosphatase treatment
under the conditions used.

However, when the alkaline phosphatase

preparation was boiled prior to addition to cell extracts (to denature
the phosphatase), inhibition of PLD and SMase was still observed
(Figure 4-1). This result suggests a non-specific inhibition by
components of the alkaline phosphatase preparation.
these data do not establish

wheth~r

Therefore,

phosphorylation is involved in

the activation of PLD and/or SMase in Jurkat cells.

In view of the

difficulties in interpreting the results of phosphatase treatment .in
crude membrane preparation, we pr9ceeded to determine whether our
anti-PLD antibody could be used to study regulation of PLD activity
more directly.

PLD in PC-3 and LNCaP Cells

Jurkat cells express relatively low levels of PLD activity,
making analysis of PLD regulation more difficult.

Our laboratory has

characterized several other cellular model systems in which PMA
activates PLD activity (Jones et al., 1994; Knoepp et aI., 1996; Ella
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at aI., 1997).

For further studies of PLD regulation, wa chose to

examine the effects of PMA on PLD activity in PC-3 and LNCaP cells
(Qi et aI., submitted).

These cells express high levels of PLD

in vitro assay

activity, as shown by the

utilizing

BPC

as the

fluorescent substrate in the presence of 1% butanol (Figure 4-2).
PLD activity was present in both PC-3 and LNCaP membranes, as
detected by production of phosphatidylbutanol (Figure 4-2).

PMA

induced increases in PLD activity in both cell lines, as detected
using intact cell assays (Qi et al., ?ubmitted).

Activation of PLD by

PMA could also be detected in membrane preparations (Qi et al.,
submitted), as was the case for Jurkat cells (Chapter 2).
The study was continued by, using the anti-PLD antibody to
identify putative PLDs.
consistently

detected

Bands migrating at 120, 95 and 50 KDa were
in

both

membranes (data not shown).

PC-3

(Figure

4-3)

and

LNCaP

The 120-KDa as well the 95-KDa band

were found mainly in membrane fractions.

The 95-KDa band could

also be detected in cytosolic fractions within these cells.

Neither

the 120-KDa band nor the 95-KOa translocated from the cytosol to
membrane upon PMA treatment.
and membranes from

A 50-KDa band is present in cytosol

a variety of cell lines (Ella, ai, and Meier,
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FIGURE 4-2.
PLD activity in mammalian cell membranes.
Membranes prepared from EL4, Jurkat, Rat-1 HIR, PC-3 and
A7r5 cells were incubated for 1 hour at 30 0 C with BPC in the
presence of 1% butanol. Reaction products were separated by thin
layer chromatography and imaged using a Fluorlmager (printed with
reverse contrast).
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FIGURE 4-3.
Immunoblot for PLD in LNCaP and PC-3 cells.
In panel A, membranes from LNCaP and PC-3 cells were
separated on SDS-PAGE and subjected to immunoblotting for PLD
using anti-PLD antibody. Castor bean PLD was used as a positive
control. Equal amounts of membrane protein were loaded in each
lane. The position of major immunoreactive PLD bands are indicated
In panel B, PC-3 cells were incubated in the absence
by arrows.
("C") and presence (UP") of 100 nM PMA for 10 minutes. Cytosol and
membrane fractions were prepared and immunoblotted with anti-PLD
antibody. The migration positions of molecular size markers are
shown on the left.
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unpublished observations}.
LNCaP (Figure 4-3).

This band was also seen in PC-3 and

The SO-KDa band likewise did not translocate in

response to PMA treatment.

Some signal transduction proteins show

apparent mobility shifts upon phosphorylation.

However, none of the

bands recognized by the anti-PLD antibody in cytosol or membranes
shifted in response to treatment of PC-3 cells with PMA.
In order to study effects of agonists on PLD phosphorylation or
protein-protein
extremely

interactions,

useful.

We

an

tested

immunoprecipitating
the

ability

of

our

antibody

is

antibody

to

immunoprecipitate PLD by performing immunoprecipitations under
standard and denaturing conditions.
immunoprecipitated
antibody.
unable

to

protein

by

We tested for the presence of

immunoblotting

with

the

same

Unfortunately, we found that the anti-PLD antibody was
immunoprecipitate

PLD

(Figure

4-4).

Although

the

sequence recognized by the antibody is near the c-terminus, its high
degree of conservation suggests that it may lie within the catalytic
site.

Thus, the epitope may not be available for recognition by the

antibody

under non-denaturing

conditions.

The

inability of the

antibody to immunoprecipitate protein under denaturing conditions
suggests low affinity of the antibody for PLD.
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4-4.
FIGURE
Immunoblots
for
PLD
in
PLD
i m m uno p ree i p it ates.
PLD was immunoprecipitated under non-denaturing conditions
from whole-cell extracts prepared from PC-3 cells that had been
incubated with (UP") or without ("C") 100 nM PMA for 10 minutes.
Lanes labelled (Urn") were mock immunoprecipitations of untreated
cells performed without PLD antibody. The immunoprecipitates, and
the immunoprecipitation supernatants, were subjected to
immunoblotting for PLD.
Whole-cell extract from untreated cells
were also immunoblotted with anti-PLD antibody (far left lane). The
position of the major immunoreactive PLD bands, PKCa, and IgG are
indicated by arrows. The positions of molecular size markers are
indicated on the left.
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An alternative approach to analyzing potential interactions
between

PLD

and

PKC

i m m u no p reci p ita ted

interactions

was

tested.

whole-cell

from

PKCex was

extracts.

The

immunoprecipitates were immunoblotted with the anti-PLD antibody
to determine whether PLD associated with PKCex.

In the experiment

shown, PMA slightly enhanced levels of the 95-KDa species in PKC
immunprecipitates

(Figure

immunoreactive

PLD

immunoprecipitates
treatment.

was

4-5).

However,

the

proteins

detected

in

not

consistently

amount

of

anti-PKCex

increased

by

PMA

While the IgG signal obscures detection of the 50-KDa

band in this particular blot, no evidence for association of this
protein with PKCa was obtained in additional experiments.
PKCa immunoprecipitates were also analyzed for PLD activity,
using the In vitro fluorescent assay.
detected

in

the

Although PLD activity could be

immunoprecipitates,

increase in PLD activity in anti-PKCa
PMA-treated cells (Figure 4-6).

there

was

no

significant

immunoprecipitates

from

Taken together, these results

suggest that PMA does not enhance or promote the direct association
of PKCa with PLD isoforms in PC-3 cells.
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FIGURE
Immunoblots
to r
PLD
in
PKCa
i m m uno prec i p it ates.
P K C ex was immunoprecipitated from whole-cell extracts
prepared from PC-3 cells that had been incubated with ("P") or
without ("C") 100 nM PMA for 10 minutes. Lanes labelled "m" were
mock immunoprecipitations performed without PKCex antibody. The
immunoprecipitates, and the immunoprecipitation supernatants,
were subjected to immunoblotting for PLD and PKCex. Whole-cell
extract from untreated cells were also immunoblotted with antiPLD antibody (far left lane).
The position of the major
immunoreactive PLD bands, PKCa, and IgG are indicated by arrows.
The positions of molecular size markers are indicated on the left.
Similar results were obtained in seven different experiments.
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FIGURE 4-6.
PLD activity in PKCa immunoprecipitates
P K C (l was immunoprecipitated from whole-cell extracts
prepared from PC-3 cells that had been incubated with or without
100 nM PMA for 10 minutes.
Mock immunoprecipitations were
The immunoprecipitates were
performed without PKCa antibody.
resuspended in lysis buffer and PLD activity was assessed using the
in vitro fluorescent assay. Data are expressed as the percent of
total fluorescence present in phosphatidylbutanol (PSt) band.
Similar results were obtained in two separate experiments.
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4-4.

Discussion
Previous studies have shown that PLD activity is expressed in

a number of mammalian cell systems.

PLD is generally activated in

response to phorbol esters that activate PKC.

In this study, we have

examined some of the potential mechanisms by which PKCs may
activate PLD.
We

have

attempted

to

determine

whether

protein

phosphorylation is involved in the activation of PLD. We have
characterized the expression of PLD using an anti-PLD antibody in
Jurkat, PC-3 and LNCaP cells.

Using immunoblotting techniques, we

have found that each cell line expresses a 120-KDa PLD that may
represent

the

cloned

human

PLD1

(Hammond

et al., 1995).

Confirmation that this protein is indeed hPLD1 will depend on the
development of additional anti-PLD antibodies and/or use of RT -PCR
to confirm expression of hPLD1 in PC-3 cells.

The 95-kDa band may

represent a form of PLD similiar in size to the plant enzyme (Wang

et al., 1994). In addition, we have identified a 50-kDa band that may
be an additional isoform of PLD.

When PLD was partially purified

from mouse lung membranes, a 50-kDa immunoreactive band eluted
in fractions containing PLD activity (Ella
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et al., submitted).

While it

is possible that this band represents a proteolytic product, this
seems

unlikely in view of the inclusion of multiple protease

inhibitors in the tissue extracts.
Our studies

using

alkaline phosphatase did

not provide

evidence for a role for dephosphorylation in PMA-induced PLD
activity.

Although alkaline phosphatase acts as a general protein

phosphatase, it is possible that it does not dephosphorylate residues
Use of other phosphatase

involved in the regulation of PLD activity.

preparations or incubation protocols may circumvent the problem of
non-specific decreases in PLD activity.

A more direct approach to

examining PLD phosphorylation would be to use anti-PLD antibodies
in immunoprecipitate PLD from [32P]-labeled cells.
must

await

Alternatively,

development
epitope-tagged

of

This approach

immunoprecipitating

antibodies.

PLDs could be immunoprecipitated

from [32P]-labeled celts transfected with constructs encoding the
tagged enzyme.
determine

if

Therefore, further approaches will be required to

phosphorylation,

or

any

other

covalent

modifications, are involved in the activation of PLD.

protein

The 120 .. kDa

and 50-kDa bands seen in Jurkat and PC-3 cells did not shift in
electrophoretic mobility following PMA treatment.
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Although some

signal transduction proteins shift when phosphorylated, others do
not.

Therefore, these results further suggest, but do not prove, that

protein phosphorylation may not be involved in the regulation of PLD.
Until additional mammalian forms of PLD have been sequenced, it
will not be possible to establish that all of the bands observed
represent PLDs.
This study has also examined the interaction of PLD with
P KCa. Our observations provided no direct evidence for association
of PKCa with PLD.
results.

Several factots may be responsible for these

First, the anti-PKCa antibody used may not permit co-

precipitation of PKCa and PLD under the conditions used.

Second,

since it has been suggested in the literature that several isoforms
of PLD exist (Hammond et al., 1995; Morris et a/., 1996), it is
possible that the forms of PLD recognized by the antibody in PC-3
cells

do

not

require

or

interact

with

PKC

for

activation.

Experiments are in progress in our laboratory to define the form(s)
of PLD expressed in Jurkat and PC-3 cells. Third, it has not been
established that PLD is selectively regulated by PKCa in this cell
line.
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While

further

studies

will

be

required

to

elucidate

the

mechanism by which PKC regulates PLD in mammalian cells, our
results are consistent with the general hypothesis that PLDs are
regulated

via

G-protein

interactions

interactions.
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or

other

protein-protein

CHAPTER 5
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Discussion

and
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Future

Directions

5-1

Conclusions
Several

presented

major conclusions

can

in the previous chapters.

be drawn
First,

from

the

data

It has been clearly

established in this work that the expression of phorbol estersensitive PLD activity varies between different T-Iymphocyte cell
lines.

Activation of PLD is not required for PKC-mediated ERK

activation, and elevation of PA is not sufficient to activate ERKs.
This was found to be the case in vascular smooth muscle cells
(Jones et al. , 1994) and fibroblasts.> (Knoepp et al., 1996), as well as
in T-cell lines (Bradshaw et al. , 1996a).
Second, it has been determined that activation of neutral
SMase can be detected in EL4 and Jurkat T-cells in response to the
antileukemic drug,

Ara-C,

(Bradshaw et al. , 1996b).

using

an

in vitro fluorescent assay

Ara-C does not result in activation of

ERKs, and activates JNKs only after a lag of approximately 1 hour.
Thus, it is possible that accumulation of ceramide as a result of
SMase activation is a direct or indirect signal for JNK activation.
Finally, these studies showed that translocation of PLD from
cytosol to membranes is probably not involved in activation of PLD
by PMA.

As observed for both Jurkat and PC-3 cells, a 120 kDa
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protein

recognized

by

an

anti-PLD

antibody

is

constitutively

localized to the membrane (Bradshaw et aI., 1996a; Qi et al.,
submitted).

Our

studies

did

not

establish

whether

phosphorylation was required for PLD or SMase activation.

protein
A direct

interaction between PLD and PKCa was not detected.
This study is the first to examine the role of PLD and SMase in
MAPK activation in T-Iymphocytes.

Overall, our findings from this

project suggest that PLD and SMase are independently activated, and
thus represent distinct signaling pathways in T-cells.

The results

of this study contribute to our understanding of T-cell activation
and death.

Furthermore, the information obtained from this study

provides additional

knowledge

regarding

the

basic mechanisms

involved in the activation of PLO, SMase, ERKs, and JNKs.

5-2.

Implications

and

future

directions

An increasing number of studies have been initiated over the
past few years to elucidate the involvement of PLD and SMase in
cellular signaling

processes.

Studies of

PLD

regulation

have

suggested a role for PLD in intracellular protein trafficking and

mitogenic signaling, and have established that members of the ARF
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and Rho families of G-proteins can regulate PLDs (Morris et al. ,
1996).

Studies of the sphingomyelin cycle have implicated SMase in

inflammatory responses, differentiation, and apoptotic cell death
(Hannun, 1994).

Even with the large amount of accumulated

knowledge concerning PLD and SMase, further studies are still
necessary to understand the roles of these enzymes in biological
processes.
In T-cells, very little is known about the roles of PLD and
SMase

in

signal

transduction. ;- Therefore,

this

thesis

project

addressed the hypothesis that PLD and SMase are involved in T-cell
signalling.

The goals of this project were to: 1) examine the

activation state of PLD using the tumor promoter, PMA, as a model
compound for the study, 2) examine the activation state of SMase
using an antileukemic drug, Ara-C, as a model compound for the
study, 3) examine the role(s) of PLD and SMase in activations of
ERKs and JNKs, and 4) examine mechanisms underlying the activation
of PLD and SMase.
EL4 (a murine thymoma cell line that is phorbol estersensitive) and Jurkat (a human cell line derived from an acute T-cell
leukemia) were primarily used as model systems for this study.
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Jurkat cells are widely used as a model to examine the requirements
of normal T-cell activation.

These cell lines differ from normal T-

cells in that they do not require IL-2 for proliferation.

They differ

from each other in their requirements for activation of IL-2 gene
expression.

Jurkat cells do not respond to PMA alone nor PMA plus

IL-1,

do

but

produce

IL-2

in

response

to

PMA

plus

phytohemagglutinin or PMA plus calcium ionophore (Baldari et al.,
1991)

EL4 cells respond to high concentrations of PMA alone, or to a

suboptimal concentration of PMA in combination with either IL-1 or
calcium ionophore, to produce IL-2.
EL4 cells in that they lack IL-1

Jurkat cells thus differ from
receptors and require calcium

mobilization for IL-2 gene activation (Baldari et al., 1991).

It is

thought that IL-2-independent growth in these cell lines results
from constitutive activation of a transcription factor, such as NFAT.
However, the early signal transduction events observed in response
to cytokines or PMA/ionomycin appear analogous to those observed
In mature T-cells.
Our studies analyzing PLD and SMase activity have led to the
finding that these enzymes are indeed regulated through different
signaling systems in Jurkat and EL4.
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Our studies provide substantial

evidence that a great deal of variablity exists for phorbol esterinduced PLD activity in different T-cell lines.

This variability may

be due to differences in expression of various PLD isoforms

(Chapter 2).

We have shown that phorbol ester-stimulated PLD

activity is present in human Jurkat leukemic T-cells, but is absent
in murine EL4 cells. Calcium, ARF, and/or GTPrs, which are known to
be required for some forms of PLO, did not stimulate PLD activity in
EL4 membranes.

Several other T-cell lines tested, such as HT-2,

also lacked phorbol ester-induced PlD activity_

Likewise, additional

studies in our laboratory have shown that basal PLD activity is
absent in human and murine peripheral T-cells (Ella et al., 1994).
These data are similiar to those obtained by Kinsky and co-workers
(1989), who showed that human peripheral blood lymphocytes lacked
phorbol ester-stimulated PLD activity.

On the other hand, work in

our laboratory showed high levels of PLD in mouse thymus (Ella e t
al., 1994).

Since thymocytes comprise the bulk of thymic tissue,

these results suggest that the expression of PLD activity is
terminated at some paint during T-cell differentiation.
Studies of the regulation of PLD have been complicated by the
likelihood that multiple isoforms of PLD exist in both cytosol and
141

membranes of mammalian cells (Siddiqui et al., 1995).
suggested at least two subclasses of PLD enzymes.

Studies have
These include

ARF-activated and Rho-activated PLD enzymes, and those enzymes
that are sensitive to fatty acids, such as oleate (Morris et al., 1996).
Thus far, genes encoding PC-specific PLD activity in plants, PChydrolyzing PLD1 in yeast, and PIP2/ARF-activated hPLD1 in humans
have been isolated and cloned (Wang et al., 1994; Morris et al., 1996;
Hammond et al., .1997; Ella ef al. , 1996).

Using this information, our

laboratory raised an anti-PLD antibody corresponding to residues
found in yeast PLD1 and hPLD1.

We were able to detect several

immunoreactive proteins of molecular weight 120, 95, and 50-kOain
Jurkat and HL-60 cells (Chapter 2) using the anti-PLD antibody.
These proteins could also be seen in the PC-3 and LNCaP prostate
cancer cell lines, which express high levels of phorbol ester-induced
PLD activity (Chapter 4).
following conclusions:

Our results from these studies lead to the
1)

some cells lack PMA-activated

PLD

activity and 2) the lack of expression of PLD isoforms In T -cells
may

be

responsible

for

absence

of

PLD

activity.

A better

understanding of factors affecting the expression and regulation of
PLDs is necessary for future advances in this area.
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Some

studies

have

shown

PKC-dependent,

phosphorylation-independent, activation of PLDs.

but

We were unable to

show any direct evidence for the association of PKCa with PLDs
(Chapter 4).

Until additional forms of mammalian PLDs are isolated

and sequenced,

and additional antibodies developed, it will be

difficult to establish the mechanisms responsible for PKC-mediated
regulation of PLD activity.
Our in vitro studies of SMase activity have established that
this enzyme is regulated independently of PLD activation in T -cells.
This project has revealed that a magnesium-dependent SMase is
activated in EL4 and Jurkat T-cells in response to treatment with
Ara-C, an anti-leukemic drug.

The activity was found solely in

membrane preparations and was maximal at neutral pH.
activity was

not affected

by treatment of cells with

SMase
the

PKC

activator phorbol ester, or by treatment with calcium ionophore.
These results confirm our hypothesis that PLD and SMase are
independently activated.

The mechanism of SMase activation has not

Progress in this area is limited by a lack of

been established.

molecular information concerning the structure of neutral SMase.
The

roles

of

PLD

and

SMase
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activation

in

the

MAPK

phosphorylation cascade have not been clearly defined in T-cells.
The results discussed in Chapters 2 and 3 showed a lack of
correlation

between the activation

activation of ERKs.

of PLD or SMase and the

It is possible that the PA generated by PLD

contributes to, but is not required for, Rat activation.

Our study

shows that ceramide does not affect the ERK phosphorylation
cascade in Jurkat and EL4 cells.

These results are consistent with

the

ceramide

general

proliferative.

hypothesis

that

generation

is

anti-

This hypothesis was further confirmed by the ability

of C2-ceramide to partially induce DNA fragmentation, a hallmark of
apoptosis, in EL4 cells (data not shown).

We were however, unable

to detect significant nuclear morphological changes associated with
apoptosis in either Jurkat or EL4 in response to Ara-C or ceramides
using microscopy techniques.
In T-cells, JNKs are synergistically activated by PKC- and
calcium-mediated pathways (Su ef al. , 1994).

We were able to

detect a similiar synergism in EL4 cells, which lack PLD activity,
upon treatment with PMA and calcium.

This suggested that PLD is

not required for the activation of JNK.

Likewise, the fact that

calcium did not induce a synergistic activation of PLD also suggests
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that JNK does not play a role in the activation of PLD.
The involvement of SMase in JNK activation was, however,
quite different from that of PLD.

Even though JNK was not activated

at early time points when SMase activation was initiated, we were
able to detect JNK activity after prolonged treatment with Ara-C.
Since SMase activity remains elevated for prolonged time in EL4 and
Jurkat, these results are consistent with recent data suggesting
that the accumulation of ceramide may induce cellular responses in
non-lymphocytic

cells.

However,

since

addition

of

high

concentrations of cell-permeable ceramides did not activate JNKs,
the role of SMase activation in Ara-C-induced JNK activation remain
unclear.

Prolonged activation of JNKs may result in apoptosis, as

suggested by work from other laboratories (Parks et al., 1996; Testi,
1996).
have

However, it should be noted that the roles of ERKs and JNKs
not

been

completely

elucidated

in

T -cells,

where

JNK

activation is associated with proliferation and ERK activation is not
required for proliferation"
It is possible that PLD may be involved In proliferative
responses in T-cells
responses.

1

while SMase is involved in anti-proliferative

Such observations could be beneficial not only in
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developing new therapeutic approaches, but in developing a better
understanding of apoptosis and growth suppression in T -cells In
correlation with pathogenesis.

Further studies will be needed to

establish the linkage between activations of SMase and JNK In
different cell types in order to elucidate the role{s) of SMase in cell
death.

Determination of the various mammalian isoforms of PLD,

inhibitors of the enzymes, and interrelationship of the enzymes with
various kinases will be necessary to provide targets for future drug
development and clinical advancements.

While similar studies of

neutral SMase are only in their early stages, this enzyme is likely to
emerge as an important clinical target in the future.
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